<?xml version="1.0" encoding="UTF-8" standalone="no"?><document setID="10db92f9-2300-4a80-836b-673e1ae91610"><labelDrug name="Xarelto"><Normalization><mmtx cui="C3159309" preferredWord="Xarelto" semType="phsu, orch"/></Normalization></labelDrug><generic name="rivaroxaban"/><sentence id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.1" text="XARELTO (rivaroxaban) tablet, film coated" type="negative"><entity charOffset="0:7" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.1.e.0" text="xarelto" type="Biomedical_Entity"><Normalization><mmtx cui="C3159309" phraseText="XARELTO" preferredWord="Xarelto" semType="phsu, orch"/><RxNorm RxCui="1114199"/></Normalization></entity><entity charOffset="9:20" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.1.e.1" text="rivaroxaban" type="Biomedical_Entity"><Normalization><mmtx cui="C1739768" phraseText="(rivaroxaban" preferredWord="rivaroxaban" semType="phsu, orch"/><RxNorm RxCui="1114195"/></Normalization></entity><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.1.e.0" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.1.e.1"/></sentence><sentence id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.2" text="Rivaroxaban, a factor Xa inhibitor, is the active ingredient in XARELTO Tablets with the chemical name 5-Chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide." type="negative"><entity charOffset="123:126" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.2.e.0" text="oxo" type="Biomedical_Entity"><Normalization><mmtx cui="C0393003" phraseText="2-oxo-3-" preferredWord="potassium oxonate" semType="phsu, orch"/><RxNorm RxCui="1427084"/></Normalization></entity><entity charOffset="15:34" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.2.e.1" text="factor xa inhibitor" type="Biomedical_Entity"><Normalization><mmtx cui="C2825027" phraseText="a factor Xa inhibitor," preferredWord="Factor Xa Inhibitor [EPC]" semType="phsu"/><RxNorm RxCui="NA"/></Normalization></entity><entity charOffset="0:11" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.2.e.2" text="rivaroxaban" type="Biomedical_Entity"><Normalization><mmtx cui="C1739768" phraseText="Rivaroxaban," preferredWord="rivaroxaban" semType="phsu, orch"/><RxNorm RxCui="1114195"/></Normalization></entity><entity charOffset="135:138" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.2.e.3" text="oxo" type="Biomedical_Entity"><Normalization><mmtx cui="C0393003" phraseText="(3-oxo-4-morpholinyl" preferredWord="potassium oxonate" semType="phsu, orch"/><RxNorm RxCui="1427084"/></Normalization></entity><entity charOffset="64:71" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.2.e.4" text="xarelto" type="Biomedical_Entity"><Normalization><mmtx cui="C3159309" phraseText="the active ingredient in XARELTO Tablets" preferredWord="Xarelto" semType="phsu, orch"/><RxNorm RxCui="1114199"/></Normalization></entity><entity charOffset="43:60" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.2.e.5" text="active ingredient" type="Biomedical_Entity"><Normalization><mmtx cui="C1372955" phraseText="the active ingredient in XARELTO Tablets" preferredWord="Active ingredient" semType="phsu"/><RxNorm RxCui="215010"/></Normalization></entity><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.2.e.1" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.2.e.0"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.2.e.2" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.2.e.0"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.2.e.4" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.2.e.0"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.2.e.5" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.2.e.0"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.2.e.2" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.2.e.1"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.2.e.1" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.2.e.3"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.2.e.1" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.2.e.4"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.2.e.1" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.2.e.5"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.2.e.2" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.2.e.3"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.2.e.2" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.2.e.4"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.2.e.2" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.2.e.5"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.2.e.4" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.2.e.3"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.2.e.5" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.2.e.3"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.2.e.5" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.2.e.4"/></sentence><sentence id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.6" text="Premature discontinuation of any oral anticoagulant, including XARELTO, increases the risk of thrombotic events. " type="negative"><entity charOffset="63:70" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.6.e.0" text="xarelto" type="Biomedical_Entity"><Normalization><mmtx cui="C3159309" phraseText="XARELTO," preferredWord="Xarelto" semType="phsu, orch"/><RxNorm RxCui="1114199"/></Normalization></entity><entity charOffset="33:51" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.6.e.1" text="oral anticoagulant" type="Biomedical_Entity"><Normalization><mmtx cui="C0354604" phraseText="Premature discontinuation of any oral anticoagulant," preferredWord="Anticoagulants, Oral" semType="phsu, orch"/><RxNorm RxCui="NA"/></Normalization></entity><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.6.e.1" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.6.e.0"/></sentence><sentence id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.7" text="To reduce this risk, consider coverage with another anticoagulant if XARELTO is discontinued for a reason other than pathological bleeding or completion of a course of therapy (2.2, 2.6, 5.1, 14.1)." type="negative"><entity charOffset="52:65" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.7.e.0" text="anticoagulant" type="Biomedical_Entity"><Normalization><mmtx cui="C3536711" phraseText="coverage with another anticoagulant" preferredWord="Anti-coagulant [EPC]" semType="phsu"/><RxNorm RxCui="923"/></Normalization></entity><entity charOffset="69:76" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.7.e.1" text="xarelto" type="Biomedical_Entity"><Normalization><mmtx cui="C3159309" phraseText="XARELTO" preferredWord="Xarelto" semType="phsu, orch"/><RxNorm RxCui="1114199"/></Normalization></entity><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.7.e.0" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.7.e.1"/></sentence><sentence id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.9" text="Epidural or spinal hematomas have occurred in patients treated with XARELTO who are receiving neuraxial anesthesia or undergoing spinal puncture. " type="negative"><entity charOffset="68:75" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.9.e.0" text="xarelto" type="Biomedical_Entity"><Normalization><mmtx cui="C3159309" phraseText="treated with XARELTO" preferredWord="Xarelto" semType="phsu, orch"/><RxNorm RxCui="1114199"/></Normalization></entity><entity charOffset="104:114" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.9.e.1" text="anesthesia" type="Biomedical_Entity"><Normalization><mmtx cui="C0002932" phraseText="neuraxial anesthesia" preferredWord="Anesthetics" semType="phsu"/><RxNorm RxCui="239756"/></Normalization></entity><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.9.e.0" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.9.e.1"/></sentence><sentence id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.18" text="Switching from Warfarin to XARELTO - When switching patients from warfarin to XARELTO, discontinue warfarin and start XARELTO as soon as the International Normalized Ratio (INR) is below 3.0 to avoid periods of inadequate anticoagulation." type="negative"><entity charOffset="118:125" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.18.e.0" text="xarelto" type="Biomedical_Entity"><Normalization><mmtx cui="C3159309" phraseText="start XARELTO as soon" preferredWord="Xarelto" semType="phsu, orch"/><RxNorm RxCui="1114199"/></Normalization></entity><entity charOffset="78:85" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.18.e.1" text="xarelto" type="Biomedical_Entity"><Normalization><mmtx cui="C3159309" phraseText="to XARELTO," preferredWord="Xarelto" semType="phsu, orch"/><RxNorm RxCui="1114199"/></Normalization></entity><entity charOffset="15:23" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.18.e.2" text="warfarin" type="Biomedical_Entity"><Normalization><mmtx cui="C0043031" phraseText="Switching from Warfarin" preferredWord="Warfarin" semType="phsu, orch, hops"/><RxNorm RxCui="11289"/></Normalization></entity><entity charOffset="66:74" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.18.e.3" text="warfarin" type="Biomedical_Entity"><Normalization><mmtx cui="C0043031" phraseText="patients from warfarin" preferredWord="Warfarin" semType="phsu, orch, hops"/><RxNorm RxCui="11289"/></Normalization></entity><entity charOffset="27:34" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.18.e.4" text="xarelto" type="Biomedical_Entity"><Normalization><mmtx cui="C3159309" phraseText="to XARELTO -" preferredWord="Xarelto" semType="phsu, orch"/><RxNorm RxCui="1114199"/></Normalization></entity><entity charOffset="99:107" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.18.e.5" text="warfarin" type="Biomedical_Entity"><Normalization><mmtx cui="C0043031" phraseText="warfarin" preferredWord="Warfarin" semType="phsu, orch, hops"/><RxNorm RxCui="11289"/></Normalization></entity><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.18.e.2" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.18.e.0"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.18.e.3" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.18.e.0"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.18.e.5" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.18.e.0"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.18.e.2" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.18.e.1"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.18.e.3" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.18.e.1"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.18.e.1" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.18.e.5"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.18.e.2" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.18.e.4"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.18.e.4" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.18.e.3"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.18.e.4" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.18.e.5"/></sentence><sentence id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.19" text="Switching from XARELTO to Warfarin - No clinical trial data are available to guide converting patients from XARELTO to warfarin. " type="negative"><entity charOffset="108:115" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.19.e.0" text="xarelto" type="Biomedical_Entity"><Normalization><mmtx cui="C3159309" phraseText="converting patients from XARELTO" preferredWord="Xarelto" semType="phsu, orch"/><RxNorm RxCui="1114199"/></Normalization></entity><entity charOffset="26:34" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.19.e.1" text="warfarin" type="Biomedical_Entity"><Normalization><mmtx cui="C0043031" phraseText="to Warfarin -" preferredWord="Warfarin" semType="phsu, orch, hops"/><RxNorm RxCui="11289"/></Normalization></entity><entity charOffset="15:22" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.19.e.2" text="xarelto" type="Biomedical_Entity"><Normalization><mmtx cui="C3159309" phraseText="Switching from XARELTO" preferredWord="Xarelto" semType="phsu, orch"/><RxNorm RxCui="1114199"/></Normalization></entity><entity charOffset="119:127" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.19.e.3" text="warfarin" type="Biomedical_Entity"><Normalization><mmtx cui="C0043031" phraseText="to warfarin." preferredWord="Warfarin" semType="phsu, orch, hops"/><RxNorm RxCui="11289"/></Normalization></entity><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.19.e.1" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.19.e.0"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.19.e.0" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.19.e.3"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.19.e.2" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.19.e.1"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.19.e.2" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.19.e.3"/></sentence><sentence id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.20" text="XARELTO affects INR, so INR measurements made during coadministration with warfarin may not be useful for determining the appropriate dose of warfarin. " type="negative"><entity charOffset="142:150" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.20.e.0" text="warfarin" type="Biomedical_Entity"><Normalization><mmtx cui="C0043031" phraseText="the appropriate dose of warfarin." preferredWord="Warfarin" semType="phsu, orch, hops"/><RxNorm RxCui="11289"/></Normalization></entity><entity charOffset="75:83" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.20.e.1" text="warfarin" type="Biomedical_Entity"><Normalization><mmtx cui="C0043031" phraseText="with warfarin" preferredWord="Warfarin" semType="phsu, orch, hops"/><RxNorm RxCui="11289"/></Normalization></entity><entity charOffset="0:7" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.20.e.2" text="xarelto" type="Biomedical_Entity"><Normalization><mmtx cui="C3159309" phraseText="XARELTO" preferredWord="Xarelto" semType="phsu, orch"/><RxNorm RxCui="1114199"/></Normalization></entity><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.20.e.2" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.20.e.0"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.20.e.2" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.20.e.1"/></sentence><sentence id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.21" text="One approach is to discontinue XARELTO and begin both a parenteral anticoagulant and warfarin at the time the next dose of XARELTO would have been taken." type="negative"><entity charOffset="67:80" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.21.e.0" text="anticoagulant" type="Biomedical_Entity"><Normalization><mmtx cui="C0003280" phraseText="both a parenteral anticoagulant" preferredWord="Anticoagulants" semType="phsu"/><RxNorm RxCui="923"/></Normalization></entity><entity charOffset="31:38" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.21.e.1" text="xarelto" type="Biomedical_Entity"><Normalization><mmtx cui="C3159309" phraseText="XARELTO" preferredWord="Xarelto" semType="phsu, orch"/><RxNorm RxCui="1114199"/></Normalization></entity><entity charOffset="123:130" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.21.e.2" text="xarelto" type="Biomedical_Entity"><Normalization><mmtx cui="C3159309" phraseText="the next dose of XARELTO" preferredWord="Xarelto" semType="phsu, orch"/><RxNorm RxCui="1114199"/></Normalization></entity><entity charOffset="85:93" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.21.e.3" text="warfarin" type="Biomedical_Entity"><Normalization><mmtx cui="C0043031" phraseText="warfarin at the time" preferredWord="Warfarin" semType="phsu, orch, hops"/><RxNorm RxCui="11289"/></Normalization></entity><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.21.e.1" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.21.e.0"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.21.e.0" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.21.e.2"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.21.e.0" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.21.e.3"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.21.e.1" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.21.e.3"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.21.e.3" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.21.e.2"/></sentence><sentence id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.22" text="Switching from XARELTO to Anticoagulants other than Warfarin - For patients currently taking XARELTO and transitioning to an anticoagulant with rapid onset, discontinue XARELTO and give the first dose of the other anticoagulant (oral or parenteral) at the time that the next XARELTO dose would have been taken [see Drug Interactions (7.3)]" type="negative"><entity charOffset="169:176" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.22.e.0" text="xarelto" type="Biomedical_Entity"><Normalization><mmtx cui="C3159309" phraseText="XARELTO" preferredWord="Xarelto" semType="phsu, orch"/><RxNorm RxCui="1114199"/></Normalization></entity><entity charOffset="52:60" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.22.e.1" text="warfarin" type="Biomedical_Entity"><Normalization><mmtx cui="C0043031" phraseText="other than Warfarin -" preferredWord="Warfarin" semType="phsu, orch, hops"/><RxNorm RxCui="11289"/></Normalization></entity><entity charOffset="15:22" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.22.e.2" text="xarelto" type="Biomedical_Entity"><Normalization><mmtx cui="C3159309" phraseText="Switching from XARELTO" preferredWord="Xarelto" semType="phsu, orch"/><RxNorm RxCui="1114199"/></Normalization></entity><entity charOffset="275:282" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.22.e.3" text="xarelto" type="Biomedical_Entity"><Normalization><mmtx cui="C3159309" phraseText="the next XARELTO dose" preferredWord="Xarelto" semType="phsu, orch"/><RxNorm RxCui="1114199"/></Normalization></entity><entity charOffset="125:138" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.22.e.4" text="anticoagulant" type="Biomedical_Entity"><Normalization><mmtx cui="C0003280" phraseText="transitioning to an anticoagulant" preferredWord="Anticoagulants" semType="phsu"/><RxNorm RxCui="923"/></Normalization></entity><entity charOffset="214:227" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.22.e.5" text="anticoagulant" type="Biomedical_Entity"><Normalization><mmtx cui="C3536711" phraseText="other anticoagulant" preferredWord="Anti-coagulant [EPC]" semType="phsu"/><RxNorm RxCui="923"/></Normalization></entity><entity charOffset="93:100" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.22.e.6" text="xarelto" type="Biomedical_Entity"><Normalization><mmtx cui="C3159309" phraseText="XARELTO" preferredWord="Xarelto" semType="phsu, orch"/><RxNorm RxCui="1114199"/></Normalization></entity><entity charOffset="26:40" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.22.e.7" text="anticoagulants" type="Biomedical_Entity"><Normalization><mmtx cui="C0003280" phraseText="to Anticoagulants" preferredWord="Anticoagulants" semType="phsu"/><RxNorm RxCui="923"/></Normalization></entity><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.22.e.1" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.22.e.0"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.22.e.4" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.22.e.0"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.22.e.0" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.22.e.5"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.22.e.7" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.22.e.0"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.22.e.2" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.22.e.1"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.22.e.1" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.22.e.3"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.22.e.1" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.22.e.4"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.22.e.1" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.22.e.5"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.22.e.1" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.22.e.6"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.22.e.7" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.22.e.1"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.22.e.2" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.22.e.4"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.22.e.2" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.22.e.5"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.22.e.2" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.22.e.7"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.22.e.4" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.22.e.3"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.22.e.5" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.22.e.3"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.22.e.7" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.22.e.3"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.22.e.6" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.22.e.4"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.22.e.7" e2=""/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.22.e.6" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.22.e.5"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.22.e.7" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.22.e.5"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.22.e.7" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.22.e.6"/></sentence><sentence id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23" text="Switching from Anticoagulants other than Warfarin to XARELTO - For patients currently receiving an anticoagulant other than warfarin, start XARELTO 0 to 2 hours prior to the next scheduled evening administration of the drug (e.g., low molecular weight heparin or non-warfarin oral anticoagulant) and omit administration of the other anticoagulant. " type="negative"><entity charOffset="124:132" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.0" text="warfarin" type="Biomedical_Entity"><Normalization><mmtx cui="C0043031" phraseText="an anticoagulant other than warfarin," preferredWord="Warfarin" semType="phsu, orch, hops"/><RxNorm RxCui="11289"/></Normalization></entity><entity charOffset="333:346" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.1" text="anticoagulant" type="Biomedical_Entity"><Normalization><mmtx cui="C3536711" phraseText="other anticoagulant." preferredWord="Anti-coagulant [EPC]" semType="phsu"/><RxNorm RxCui="923"/></Normalization></entity><entity charOffset="15:29" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.2" text="anticoagulants" type="Biomedical_Entity"><Normalization><mmtx cui="C0003280" phraseText="Switching from Anticoagulants" preferredWord="Anticoagulants" semType="phsu"/><RxNorm RxCui="923"/></Normalization></entity><entity charOffset="99:112" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.3" text="anticoagulant" type="Biomedical_Entity"><Normalization><mmtx cui="C3536711" phraseText="an anticoagulant other than warfarin," preferredWord="Anti-coagulant [EPC]" semType="phsu"/><RxNorm RxCui="923"/></Normalization></entity><entity charOffset="41:49" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.4" text="warfarin" type="Biomedical_Entity"><Normalization><mmtx cui="C0043031" phraseText="other than Warfarin" preferredWord="Warfarin" semType="phsu, orch, hops"/><RxNorm RxCui="11289"/></Normalization></entity><entity charOffset="267:275" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.5" text="warfarin" type="Biomedical_Entity"><Normalization><mmtx cui="C0043031" phraseText="non-warfarin oral anticoagulant" preferredWord="Warfarin" semType="phsu, orch, hops"/><RxNorm RxCui="11289"/></Normalization></entity><entity charOffset="276:294" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.6" text="oral anticoagulant" type="Biomedical_Entity"><Normalization><mmtx cui="C0354604" phraseText="non-warfarin oral anticoagulant" preferredWord="Anticoagulants, Oral" semType="phsu, orch"/><RxNorm RxCui="NA"/></Normalization></entity><entity charOffset="231:259" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.7" text="low molecular weight heparin" type="Biomedical_Entity"><Normalization><mmtx cui="C3536766" phraseText="low molecular weight heparin" preferredWord="Low Molecular Weight Heparin [EPC]" semType="phsu"/><RxNorm RxCui="1023523"/></Normalization></entity><entity charOffset="53:60" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.8" text="xarelto" type="Biomedical_Entity"><Normalization><mmtx cui="C3159309" phraseText="to XARELTO -" preferredWord="Xarelto" semType="phsu, orch"/><RxNorm RxCui="1114199"/></Normalization></entity><entity charOffset="140:147" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.9" text="xarelto" type="Biomedical_Entity"><Normalization><mmtx cui="C3159309" phraseText="start XARELTO 0 to 2 hours" preferredWord="Xarelto" semType="phsu, orch"/><RxNorm RxCui="1114199"/></Normalization></entity><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.0" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.1"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.2" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.0"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.3" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.0"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.0" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.6"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.0" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.7"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.8" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.0"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.0" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.9"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.2" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.1"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.4" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.1"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.5" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.1"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.6" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.1"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.7" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.1"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.8" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.1"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.9" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.1"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.2" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.3"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.2" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.4"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.2" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.5"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.2" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.6"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.2" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.7"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.2" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.8"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.2" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.9"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.4" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.3"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.3" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.5"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.3" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.6"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.3" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.7"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.8" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.3"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.3" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.9"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.4" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.6"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.4" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.7"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.4" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.8"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.4" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.9"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.5" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.6"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.7" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.5"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.8" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.5"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.9" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.5"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.7" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.6"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.8" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.6"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.9" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.6"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.8" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.7"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.9" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.23.e.7"/></sentence><sentence id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.24" text="For unfractionated heparin being administered by continuous infusion, stop the infusion and start XARELTO at the same time." type="negative"><entity charOffset="98:105" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.24.e.0" text="xarelto" type="Biomedical_Entity"><Normalization><mmtx cui="C3159309" phraseText="start XARELTO at the same time." preferredWord="Xarelto" semType="phsu, orch"/><RxNorm RxCui="1114199"/></Normalization></entity><entity charOffset="4:26" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.24.e.1" text="unfractionated heparin" type="Biomedical_Entity"><Normalization><mmtx cui="C2825026" phraseText="For unfractionated heparin" preferredWord="Unfractionated Heparin [EPC]" semType="phsu"/><RxNorm RxCui="1036221"/></Normalization></entity><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.24.e.1" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.24.e.0"/></sentence><sentence id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.52" text="Since rivaroxaban absorption is dependent on the site of drug release, avoid administration of XARELTO distal to the stomach which can result in reduced absorption and thereby, reduced drug exposure. " type="negative"><entity charOffset="6:17" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.52.e.0" text="rivaroxaban" type="Biomedical_Entity"><Normalization><mmtx cui="C1739768" phraseText="rivaroxaban absorption" preferredWord="rivaroxaban" semType="phsu, orch"/><RxNorm RxCui="1114195"/></Normalization></entity><entity charOffset="95:102" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.52.e.1" text="xarelto" type="Biomedical_Entity"><Normalization><mmtx cui="C3159309" phraseText="administration of XARELTO" preferredWord="Xarelto" semType="phsu, orch"/><RxNorm RxCui="1114199"/></Normalization></entity><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.52.e.0" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.52.e.1"/></sentence><sentence id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.55" text="An in vitro compatibility study indicated that there is no adsorption of rivaroxaban from a water suspension of a crushed XARELTO tablet to PVC or silicone nasogastric (NG) tubing." type="negative"><entity charOffset="122:129" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.55.e.0" text="xarelto" type="Biomedical_Entity"><Normalization><mmtx cui="C3159309" phraseText="of a crushed XARELTO tablet" preferredWord="Xarelto" semType="phsu, orch"/><RxNorm RxCui="1114199"/></Normalization></entity><entity charOffset="73:84" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.55.e.1" text="rivaroxaban" type="Biomedical_Entity"><Normalization><mmtx cui="C1739768" phraseText="no adsorption of rivaroxaban" preferredWord="rivaroxaban" semType="phsu, orch"/><RxNorm RxCui="1114195"/></Normalization></entity><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.55.e.1" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.55.e.0"/></sentence><sentence id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.62" text="Premature discontinuation of any oral anticoagulant, including XARELTO, in the absence of adequate alternative anticoagulation increases the risk of thrombotic events. " type="negative"><entity charOffset="33:51" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.62.e.0" text="oral anticoagulant" type="Biomedical_Entity"><Normalization><mmtx cui="C0354604" phraseText="Premature discontinuation of any oral anticoagulant," preferredWord="Anticoagulants, Oral" semType="phsu, orch"/><RxNorm RxCui="NA"/></Normalization></entity><entity charOffset="63:70" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.62.e.1" text="xarelto" type="Biomedical_Entity"><Normalization><mmtx cui="C3159309" phraseText="XARELTO," preferredWord="Xarelto" semType="phsu, orch"/><RxNorm RxCui="1114199"/></Normalization></entity><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.62.e.0" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.62.e.1"/></sentence><sentence id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.63" text="An increased rate of stroke was observed during the transition from XARELTO to warfarin in clinical trials in atrial fibrillation patients. " type="negative"><entity charOffset="79:87" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.63.e.0" text="warfarin" type="Biomedical_Entity"><Normalization><mmtx cui="C0043031" phraseText="to warfarin" preferredWord="Warfarin" semType="phsu, orch, hops"/><RxNorm RxCui="11289"/></Normalization></entity><entity charOffset="68:75" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.63.e.1" text="xarelto" type="Biomedical_Entity"><Normalization><mmtx cui="C3159309" phraseText="from XARELTO" preferredWord="Xarelto" semType="phsu, orch"/><RxNorm RxCui="1114199"/></Normalization></entity><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.63.e.1" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.63.e.0"/></sentence><sentence id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.64" text="If XARELTO is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant [see Dosage and Administration (2.2, 2.6) and Clinical Studies (14.1)]." type="negative"><entity charOffset="142:155" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.64.e.0" text="anticoagulant" type="Biomedical_Entity"><Normalization><mmtx cui="C0003280" phraseText="coverage with another anticoagulant" preferredWord="Anticoagulants" semType="phsu"/><RxNorm RxCui="923"/></Normalization></entity><entity charOffset="3:10" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.64.e.1" text="xarelto" type="Biomedical_Entity"><Normalization><mmtx cui="C3159309" phraseText="XARELTO" preferredWord="Xarelto" semType="phsu, orch"/><RxNorm RxCui="1114199"/></Normalization></entity><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.64.e.1" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.64.e.0"/></sentence><sentence id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.71" text="A specific antidote for rivaroxaban is not available. " type="negative"><entity charOffset="24:35" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.71.e.0" text="rivaroxaban" type="Biomedical_Entity"><Normalization><mmtx cui="C1739768" phraseText="A specific antidote for rivaroxaban" preferredWord="rivaroxaban" semType="phsu, orch"/><RxNorm RxCui="1114195"/></Normalization></entity><entity charOffset="11:19" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.71.e.1" text="antidote" type="Biomedical_Entity"><Normalization><mmtx cui="C0003295" phraseText="A specific antidote for rivaroxaban" preferredWord="Antidote" semType="phsu"/><RxNorm RxCui="930"/></Normalization></entity><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.71.e.1" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.71.e.0"/></sentence><sentence id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.73" text="Protamine sulfate and vitamin K are not expected to affect the anticoagulant activity of rivaroxaban. " type="negative"><entity charOffset="22:31" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.73.e.0" text="vitamin k" type="Biomedical_Entity"><Normalization><mmtx cui="C0042878" phraseText="vitamin K" preferredWord="Vitamin K" semType="phsu, lipd, vita"/><RxNorm RxCui="604318"/></Normalization></entity><entity charOffset="89:100" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.73.e.1" text="rivaroxaban" type="Biomedical_Entity"><Normalization><mmtx cui="C1739768" phraseText="the anticoagulant activity of rivaroxaban." preferredWord="rivaroxaban" semType="phsu, orch"/><RxNorm RxCui="1114195"/></Normalization></entity><entity charOffset="63:76" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.73.e.2" text="anticoagulant" type="Biomedical_Entity"><Normalization><mmtx cui="C0003280" phraseText="the anticoagulant activity of rivaroxaban." preferredWord="Anticoagulants" semType="phsu"/><RxNorm RxCui="923"/></Normalization></entity><entity charOffset="0:17" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.73.e.3" text="protamine sulfate" type="Biomedical_Entity"><Normalization><mmtx cui="C0033602" phraseText="Protamine sulfate" preferredWord="Protamine Sulfate (USP)" semType="phsu, irda, aapp"/><RxNorm RxCui="236471"/></Normalization></entity><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.73.e.0" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.73.e.1"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.73.e.0" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.73.e.2"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.73.e.3" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.73.e.0"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.73.e.2" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.73.e.1"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.73.e.3" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.73.e.1"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.73.e.3" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.73.e.2"/></sentence><sentence id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.74" text="There is no experience with antifibrinolytic agents (tranexamic acid, aminocaproic acid) in individuals receiving rivaroxaban. " type="negative"><entity charOffset="70:87" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.74.e.0" text="aminocaproic acid" type="Biomedical_Entity"><Normalization><mmtx cui="C0000608" phraseText="aminocaproic acid" preferredWord="6-Aminocaproic Acid" semType="phsu, aapp"/><RxNorm RxCui="99"/></Normalization></entity><entity charOffset="53:68" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.74.e.1" text="tranexamic acid" type="Biomedical_Entity"><Normalization><mmtx cui="C0040613" phraseText="(tranexamic acid," preferredWord="Tranexamic Acid" semType="phsu, orch"/><RxNorm RxCui="10691"/></Normalization></entity><entity charOffset="28:51" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.74.e.2" text="antifibrinolytic agents" type="Biomedical_Entity"><Normalization><mmtx cui="C0003304" phraseText="no experience with antifibrinolytic agents" preferredWord="Antifibrinolytic Agents" semType="phsu"/><RxNorm RxCui="934"/></Normalization></entity><entity charOffset="114:125" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.74.e.3" text="rivaroxaban" type="Biomedical_Entity"><Normalization><mmtx cui="C1739768" phraseText="rivaroxaban." preferredWord="rivaroxaban" semType="phsu, orch"/><RxNorm RxCui="1114195"/></Normalization></entity><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.74.e.1" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.74.e.0"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.74.e.2" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.74.e.0"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.74.e.0" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.74.e.3"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.74.e.2" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.74.e.1"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.74.e.1" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.74.e.3"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.74.e.2" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.74.e.3"/></sentence><sentence id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.75" text="There is neither scientific rationale for benefit nor experience with systemic hemostatics (desmopressin and aprotinin) in individuals receiving rivaroxaban. " type="negative"><entity charOffset="145:156" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.75.e.0" text="rivaroxaban" type="Biomedical_Entity"><Normalization><mmtx cui="C1739768" phraseText="rivaroxaban." preferredWord="rivaroxaban" semType="phsu, orch"/><RxNorm RxCui="1114195"/></Normalization></entity><entity charOffset="79:90" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.75.e.1" text="hemostatics" type="Biomedical_Entity"><Normalization><mmtx cui="C0019120" phraseText="experience with systemic hemostatics" preferredWord="Hemostatic Agents" semType="phsu"/><RxNorm RxCui="5220"/></Normalization></entity><entity charOffset="92:104" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.75.e.2" text="desmopressin" type="Biomedical_Entity"><Normalization><mmtx cui="C0011701" phraseText="(desmopressin" preferredWord="desmopressin" semType="phsu, aapp, horm"/><RxNorm RxCui="3251"/></Normalization></entity><entity charOffset="109:118" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.75.e.3" text="aprotinin" type="Biomedical_Entity"><Normalization><mmtx cui="C0003641" phraseText="aprotinin" preferredWord="Aprotinin" semType="bacs, phsu, aapp"/><RxNorm RxCui="1056"/></Normalization></entity><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.75.e.1" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.75.e.0"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.75.e.2" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.75.e.0"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.75.e.3" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.75.e.0"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.75.e.1" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.75.e.2"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.75.e.1" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.75.e.3"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.75.e.2" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.75.e.3"/></sentence><sentence id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.76" text="Use of procoagulant reversal agents such as prothrombin complex concentrate (PCC), activated prothrombin complex concentrate (APCC), or recombinant factor VIIa (rFVIIa) may be considered but has not been evaluated in clinical trials." type="negative"><entity charOffset="83:124" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.76.e.0" text="activated prothrombin complex concentrate" type="Biomedical_Entity"><Normalization><mmtx cui="C0358606" phraseText="activated prothrombin complex concentrate (APCC)," preferredWord="Factor VIII by-passing fraction products" semType="phsu"/><RxNorm RxCui="751543"/></Normalization></entity><entity charOffset="136:159" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.76.e.1" text="recombinant factor viia" type="Biomedical_Entity"><Normalization><mmtx cui="C0534191" phraseText="recombinant factor VIIa (rFVIIa)" preferredWord="recombinant FVIIa" semType="phsu, aapp"/><RxNorm RxCui="8410"/></Normalization></entity><entity charOffset="44:75" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.76.e.2" text="prothrombin complex concentrate" type="Biomedical_Entity"><Normalization><mmtx cui="C0072434" phraseText="such as prothrombin complex concentrate (PCC)," preferredWord="prothrombin complex concentrates" semType="phsu, orch"/><RxNorm RxCui="1441688"/></Normalization></entity><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.76.e.0" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.76.e.1"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.76.e.2" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.76.e.0"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.76.e.2" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.76.e.1"/></sentence><sentence biomedicalEntities="3" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.79" lineNumber="93" text="Inhibitors and inducers of these CYP450 enzymes or transporters (e.g., P-gp) may result in changes in rivaroxaban exposure." type="regular"><entity charOffset="0:63" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.79.e.0" text="Inhibitors and inducers of these CYP450 enzymes or transporters" type="Drug_Class"><Normalization><RxNorm RxCui="NA"/></Normalization></entity><entity charOffset="71:75" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.79.e.1" text="P-gp" type="Drug"><Normalization><RxNorm RxCui="71576"/></Normalization></entity><entity charOffset="102:113" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.79.e.3" text="rivaroxaban" type="Drug"><Normalization><mmtx cui="C1739768" phraseText="in rivaroxaban exposure." preferredWord="rivaroxaban" semType="phsu, orch"/><RxNorm RxCui="1114195"/></Normalization></entity><entity charOffset="91:101|114:122" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.79.e.4" text="changes in exposure" type="Specific_Interaction"/><drugClassMembership drug="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.79.e.1" drugClass="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.79.e.0"/><drugInteraction id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.79.ddi.1"><interaction trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.79.e.4"><relations><relation type="hasPrecipitant"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.79.e.0"/></relation><relation type="hasObject"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.79.e.3"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.79.e.0" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.79.e.3" trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.79.e.4" type="Specific_Interaction"/></sentence><sentence biomedicalEntities="7" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81" lineNumber="97" text="In drug interaction studies evaluating the concomitant use with drugs that are combined P-gp and CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin, erythromycin and fluconazole), increases in rivaroxaban exposure and pharmacodynamic effects (i.e., factor Xa inhibition and PT prolongation) were observed. " type="regular"><entity charOffset="64:114" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.0" text="drugs that are combined P-gp and CYP3A4 inhibitors" type="Drug_Class"><Normalization><mmtx cui="C0013227" phraseText="the concomitant use with drugs" preferredWord="Pharmaceutical Preparations" semType="phsu"/><RxNorm RxCui="NA"/></Normalization></entity><entity charOffset="116:128" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.1" text="ketoconazole" type="Drug"><Normalization><mmtx cui="C0022625" phraseText="(ketoconazole," preferredWord="Ketoconazole" semType="phsu, orch"/><RxNorm RxCui="6135"/></Normalization></entity><entity charOffset="130:139" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.2" text="ritonavir" type="Drug"><Normalization><mmtx cui="C0292818" phraseText="ritonavir," preferredWord="Ritonavir" semType="phsu, orch"/><RxNorm RxCui="85762"/></Normalization></entity><entity charOffset="141:155" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.3" text="clarithromycin" type="Drug"><Normalization><mmtx cui="C0055856" phraseText="clarithromycin," preferredWord="Clarithromycin" semType="orch, antb"/><RxNorm RxCui="21212"/></Normalization></entity><entity charOffset="157:169" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.4" text="erythromycin" type="Drug"><Normalization><mmtx cui="C0014806" phraseText="erythromycin" preferredWord="Erythromycin" semType="orch, antb"/><RxNorm RxCui="4053"/></Normalization></entity><entity charOffset="174:185" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.5" text="fluconazole" type="Drug"><Normalization><mmtx cui="C0016277" phraseText="fluconazole" preferredWord="Fluconazole" semType="phsu, orch"/><RxNorm RxCui="4450"/></Normalization></entity><entity charOffset="188:200|213:221" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.11" text="increases in exposure" type="Increase_Interaction"/><entity charOffset="201:212" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.13" text="rivaroxaban" type="Drug"><Normalization><mmtx cui="C1739768" phraseText="increases in rivaroxaban exposure" preferredWord="rivaroxaban" semType="phsu, orch"/><RxNorm RxCui="1114195"/></Normalization></entity><entity charOffset="188:200|257:277" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.14" text="increases in factor Xa inhibition" type="Specific_Interaction"/><entity charOffset="188:200|282:297" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.16" text="increases in PT prolongation" type="Specific_Interaction"/><drugClassMembership drug="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.1" drugClass="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.0"/><drugClassMembership drug="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.2" drugClass="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.0"/><drugClassMembership drug="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.3" drugClass="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.0"/><drugClassMembership drug="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.4" drugClass="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.0"/><drugClassMembership drug="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.5" drugClass="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.0"/><drugInteraction id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.ddi.1"><interaction trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.11"><relations><relation type="hasPrecipitant"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.1"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.3"/></relation><relation type="hasObject"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.13"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.4"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.2"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.5"/></relation></relations></interaction></drugInteraction><drugInteraction id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.ddi.2"><interaction trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.14"><relations><relation type="hasPrecipitant"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.3"/></relation><relation type="hasObject"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.13"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.5"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.1"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.2"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.4"/></relation></relations></interaction></drugInteraction><drugInteraction id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.ddi.3"><interaction trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.16"><relations><relation type="hasPrecipitant"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.3"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.5"/></relation><relation type="hasObject"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.13"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.1"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.2"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.4"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.1" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.13" trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.11" type="Increase_Interaction"/><pair ddi="true" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.3" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.13" trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.11" type="Increase_Interaction"/><pair ddi="true" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.4" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.13" trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.11" type="Increase_Interaction"/><pair ddi="true" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.2" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.13" trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.11" type="Increase_Interaction"/><pair ddi="true" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.5" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.13" trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.11" type="Increase_Interaction"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.1" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.3"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.1" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.4"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.1" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.2"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.1" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.5"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.3" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.4"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.2" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.3"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.3" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.5"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.2" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.4"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.4" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.5"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.2" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.5"/><pair ddi="true" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.3" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.13" trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.14" type="Specific_Interaction"/><pair ddi="true" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.5" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.13" trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.14" type="Specific_Interaction"/><pair ddi="true" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.1" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.13" trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.14" type="Specific_Interaction"/><pair ddi="true" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.2" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.13" trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.14" type="Specific_Interaction"/><pair ddi="true" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.4" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.13" trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.14" type="Specific_Interaction"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.3" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.5"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.1" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.3"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.2" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.3"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.3" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.4"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.1" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.5"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.2" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.5"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.4" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.5"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.1" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.2"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.1" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.4"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.2" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.4"/><pair ddi="true" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.3" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.13" trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.16" type="Specific_Interaction"/><pair ddi="true" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.5" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.13" trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.16" type="Specific_Interaction"/><pair ddi="true" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.1" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.13" trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.16" type="Specific_Interaction"/><pair ddi="true" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.2" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.13" trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.16" type="Specific_Interaction"/><pair ddi="true" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.4" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.13" trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.16" type="Specific_Interaction"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.3" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.5"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.1" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.3"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.2" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.3"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.3" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.4"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.1" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.5"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.2" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.5"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.4" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.5"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.1" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.2"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.1" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.4"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.2" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.4"/></sentence><sentence id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.84" text="When data suggest a change in exposure is unlikely to affect bleeding risk (e.g., clarithromycin, erythromycin), no precautions are necessary during coadministration with drugs that are combined P-gp and CYP3A4 inhibitors." type="negative"><entity charOffset="82:96" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.84.e.0" text="clarithromycin" type="Biomedical_Entity"><Normalization><mmtx cui="C0055856" phraseText="clarithromycin," preferredWord="Clarithromycin" semType="orch, antb"/><RxNorm RxCui="21212"/></Normalization></entity><entity charOffset="98:110" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.84.e.1" text="erythromycin" type="Biomedical_Entity"><Normalization><mmtx cui="C0014806" phraseText="erythromycin" preferredWord="Erythromycin" semType="orch, antb"/><RxNorm RxCui="4053"/></Normalization></entity><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.84.e.0" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.84.e.1"/></sentence><sentence biomedicalEntities="2" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.85" lineNumber="101" text="Avoid concomitant administration of XARELTO with combined P-gp and strong CYP3A4 inhibitors [see Warnings and Precautions (5.6)]." type="regular"><entity charOffset="36:43" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.85.e.0" text="XARELTO" type="Drug"><Normalization><mmtx cui="C3159309" phraseText="concomitant administration of XARELTO" preferredWord="Xarelto" semType="phsu, orch"/><RxNorm RxCui="1114199"/></Normalization></entity><entity charOffset="49:91" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.85.e.1" text="combined P-gp and strong CYP3A4 inhibitors" type="Drug_Class"><Normalization><RxNorm RxCui="67034"/></Normalization></entity><entity charOffset="0:5" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.85.e.2" text="Avoid" type="Caution_Interaction"/><drugInteraction id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.85.ddi.1"><interaction trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.85.e.2"><relations><relation type="hasPrecipitant"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.85.e.1"/></relation><relation type="hasObject"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.85.e.0"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.85.e.0" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.85.e.1" trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.85.e.2" type="Caution_Interaction"/></sentence><sentence biomedicalEntities="5" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.87" lineNumber="105" text="Results from drug interaction studies and population PK analyses from clinical studies indicate coadministration of XARELTO with a combined P-gp and strong CYP3A4 inducer (e.g., rifampicin, phenytoin) decreased rivaroxaban exposure by up to 50%. " type="regular"><anaphoraRelation><anaphoraEntity charOffset="211:222" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.87.e.8" text="rivaroxaban" type="Drug"/><antecedentEntity charOffset="116-123" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.87.e.0" text="XARELTO" type="Drug"/></anaphoraRelation><entity charOffset="116:123" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.87.e.0" text="XARELTO" type="Drug"><Normalization><mmtx cui="C3159309" phraseText="coadministration of XARELTO" preferredWord="Xarelto" semType="phsu, orch"/><RxNorm RxCui="1114199"/></Normalization></entity><entity charOffset="131:170" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.87.e.1" text="combined P-gp and strong CYP3A4 inducer" type="Drug_Class"><Normalization><RxNorm RxCui="67034"/></Normalization></entity><entity charOffset="178:188" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.87.e.2" text="rifampicin" type="Drug"><Normalization><mmtx cui="C0035608" phraseText="rifampicin," preferredWord="Rifampin" semType="orch, antb"/><RxNorm RxCui="9384"/></Normalization></entity><entity charOffset="190:199" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.87.e.3" text="phenytoin" type="Drug"><Normalization><mmtx cui="C0031507" phraseText="phenytoin" preferredWord="Phenytoin" semType="phsu, orch"/><RxNorm RxCui="8183"/></Normalization></entity><entity charOffset="201:210|223:231" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.87.e.6" text="decreased exposure" type="Decrease_Interaction"/><entity charOffset="211:222" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.87.e.8" text="rivaroxaban" type="Drug"><Normalization><mmtx cui="C1739768" phraseText="decreased rivaroxaban exposure by" preferredWord="rivaroxaban" semType="phsu, orch"/><RxNorm RxCui="1114195"/></Normalization></entity><drugClassMembership drug="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.87.e.2" drugClass="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.87.e.1"/><drugClassMembership drug="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.87.e.3" drugClass="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.87.e.1"/><drugInteraction id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.87.ddi.1"><interaction trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.87.e.6"><relations><relation type="hasObject"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.87.e.8"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.87.e.1"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.87.e.1" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.87.e.8" trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.87.e.6" type="Decrease_Interaction"/></sentence><sentence biomedicalEntities="0" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.88" lineNumber="105" text="Similar decreases in pharmacodynamic effects were also observed. " type="irregular"><entity charOffset="8:44" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.88.e.0" text="decreases in pharmacodynamic effects" type="Decrease_Interaction"/><drugInteraction id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.88.ddi.1"><interaction trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.88.e.0"><relations><relation type="hasObject"><ellipsisSentence id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.87" text="Results from drug interaction studies and population PK analyses from clinical studies indicate coadministration of XARELTO with a combined P-gp and strong CYP3A4 inducer (e.g., rifampicin, phenytoin) decreased rivaroxaban exposure by up to 50%. "><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.87.e.8"/></ellipsisSentence></relation><relation type="hasPrecipitant"><ellipsisSentence id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.87" text="Results from drug interaction studies and population PK analyses from clinical studies indicate coadministration of XARELTO with a combined P-gp and strong CYP3A4 inducer (e.g., rifampicin, phenytoin) decreased rivaroxaban exposure by up to 50%. "><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.87.e.1"/></ellipsisSentence></relation></relations></interaction></drugInteraction></sentence><sentence biomedicalEntities="6" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.90" lineNumber="107" text="Avoid concomitant use of XARELTO with drugs that are combined P-gp and strong CYP3A4 inducers (e.g., carbamazepine, phenytoin, rifampin, St. John's wort) [see Warnings and Precautions (5.6)]." type="regular"><entity charOffset="25:32" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.90.e.0" text="XARELTO" type="Drug"><Normalization><mmtx cui="C3159309" phraseText="concomitant use of XARELTO" preferredWord="Xarelto" semType="phsu, orch"/><RxNorm RxCui="1114199"/></Normalization></entity><entity charOffset="53:93" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.90.e.1" text="combined P-gp and strong CYP3A4 inducers" type="Drug_Class"><Normalization><RxNorm RxCui="67034"/></Normalization></entity><entity charOffset="101:114" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.90.e.2" text="carbamazepine" type="Drug"><Normalization><mmtx cui="C0006949" phraseText="carbamazepine," preferredWord="Carbamazepine" semType="phsu, orch"/><RxNorm RxCui="2002"/></Normalization></entity><entity charOffset="116:125" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.90.e.3" text="phenytoin" type="Drug"><Normalization><mmtx cui="C0031507" phraseText="phenytoin," preferredWord="Phenytoin" semType="phsu, orch"/><RxNorm RxCui="8183"/></Normalization></entity><entity charOffset="127:135" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.90.e.4" text="rifampin" type="Drug"><Normalization><mmtx cui="C0035608" phraseText="rifampin," preferredWord="Rifampin" semType="orch, antb"/><RxNorm RxCui="9384"/></Normalization></entity><entity charOffset="137:140|141:152" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.90.e.5" text="St. John's wort" type="Drug"><Normalization><mmtx cui="C0813171" phraseText="St. John's wort" preferredWord="ST. JOHN'S WORT EXTRACT" semType="phsu, orch"/><RxNorm RxCui="669620"/></Normalization></entity><entity charOffset="0:5" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.90.e.10" text="Avoid" type="Caution_Interaction"/><drugClassMembership drug="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.90.e.2" drugClass="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.90.e.1"/><drugClassMembership drug="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.90.e.3" drugClass="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.90.e.1"/><drugClassMembership drug="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.90.e.4" drugClass="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.90.e.1"/><drugClassMembership drug="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.90.e.5" drugClass="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.90.e.1"/><drugInteraction id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.90.ddi.1"><interaction trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.90.e.10"><relations><relation type="hasObject"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.90.e.0"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.90.e.1"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.90.e.0" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.90.e.1" trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.90.e.10" type="Caution_Interaction"/></sentence><sentence id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.91" text="7.3 Anticoagulants and NSAIDs/Aspirin" type="negative"><entity charOffset="23:29" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.91.e.0" text="nsaids" type="Biomedical_Entity"><Normalization><mmtx cui="C0003211" phraseText="NSAIDs/Aspirin" preferredWord="Anti-Inflammatory Agents, Non-Steroidal" semType="phsu"/><RxNorm RxCui="889"/></Normalization></entity><entity charOffset="30:37" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.91.e.1" text="aspirin" type="Biomedical_Entity"><Normalization><mmtx cui="C0004057" phraseText="NSAIDs/Aspirin" preferredWord="Aspirin" semType="phsu, orch"/><RxNorm RxCui="1191"/></Normalization></entity><entity charOffset="4:18" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.91.e.2" text="anticoagulants" type="Biomedical_Entity"><Normalization><mmtx cui="C0003280" phraseText="7.3 Anticoagulants" preferredWord="Anticoagulants" semType="phsu"/><RxNorm RxCui="923"/></Normalization></entity><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.91.e.0" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.91.e.1"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.91.e.2" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.91.e.0"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.91.e.2" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.91.e.1"/></sentence><sentence biomedicalEntities="2" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.92" lineNumber="111" text="Single doses of enoxaparin and XARELTO given concomitantly resulted in an additive effect on anti-factor Xa activity. " type="regular"><entity charOffset="16:26" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.92.e.0" text="enoxaparin" type="Drug"><Normalization><mmtx cui="C0206460" phraseText="Single doses of enoxaparin" preferredWord="Enoxaparin" semType="phsu, carb"/><RxNorm RxCui="67108"/></Normalization></entity><entity charOffset="31:38" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.92.e.1" text="XARELTO" type="Drug"><Normalization><mmtx cui="C3159309" phraseText="XARELTO" preferredWord="Xarelto" semType="phsu, orch"/><RxNorm RxCui="1114199"/></Normalization></entity><entity charOffset="74:116" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.92.e.2" text="additive effect on anti-factor Xa activity" type="Specific_Interaction"/><drugInteraction id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.92.ddi.1"><interaction trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.92.e.2"><relations><relation type="hasPrecipitant"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.92.e.0"/></relation><relation type="hasObject"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.92.e.1"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.92.e.0" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.92.e.1" trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.92.e.2" type="Specific_Interaction"/></sentence><sentence biomedicalEntities="2" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.93" lineNumber="111" text="Single doses of warfarin and XARELTO resulted in an additive effect on factor Xa inhibition and PT. " type="regular"><entity charOffset="16:24" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.93.e.0" text="warfarin" type="Drug"><Normalization><mmtx cui="C0043031" phraseText="Single doses of warfarin" preferredWord="Warfarin" semType="phsu, orch, hops"/><RxNorm RxCui="11289"/></Normalization></entity><entity charOffset="29:36" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.93.e.1" text="XARELTO" type="Drug"><Normalization><mmtx cui="C3159309" phraseText="XARELTO" preferredWord="Xarelto" semType="phsu, orch"/><RxNorm RxCui="1114199"/></Normalization></entity><entity charOffset="52:91" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.93.e.2" text="additive effect on factor Xa inhibition" type="Specific_Interaction"/><entity charOffset="52:70|96:98" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.93.e.4" text="additive effect on PT" type="Specific_Interaction"/><drugInteraction id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.93.ddi.1"><interaction trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.93.e.2"><relations><relation type="hasPrecipitant"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.93.e.0"/></relation><relation type="hasObject"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.93.e.1"/></relation></relations></interaction></drugInteraction><drugInteraction id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.93.ddi.2"><interaction trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.93.e.4"><relations><relation type="hasPrecipitant"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.93.e.0"/></relation><relation type="hasObject"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.93.e.1"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.93.e.0" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.93.e.1" trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.93.e.2" type="Specific_Interaction"/></sentence><sentence biomedicalEntities="1" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.94" lineNumber="111" text="Concomitant aspirin use has been identified as an independent risk factor for major bleeding in efficacy trials. " type="irregular"><entity charOffset="12:19" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.94.e.0" text="aspirin" type="Drug"><Normalization><mmtx cui="C0004057" phraseText="Concomitant aspirin use" preferredWord="Aspirin" semType="phsu, orch"/><RxNorm RxCui="1191"/></Normalization></entity><entity charOffset="62:92" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.94.e.1" text="risk factor for major bleeding" type="Specific_Interaction"/><drugInteraction id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.94.ddi.1"><interaction trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.94.e.1"><relations><relation type="hasObject"><ellipsisSentence id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.93" text="Single doses of warfarin and XARELTO resulted in an additive effect on factor Xa inhibition and PT. "><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.93.e.1"/></ellipsisSentence></relation><relation type="hasPrecipitant"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.94.e.0"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="labelDrug" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.94.e.0"/></sentence><sentence biomedicalEntities="2" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.95" lineNumber="111" text="NSAIDs are known to increase bleeding, and bleeding risk may be increased when NSAIDs are used concomitantly with XARELTO. " type="regular"><entity charOffset="114:121" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.95.e.0" text="XARELTO" type="Drug"><Normalization><mmtx cui="C3159309" phraseText="concomitantly with XARELTO." preferredWord="Xarelto" semType="phsu, orch"/><RxNorm RxCui="1114199"/></Normalization></entity><entity charOffset="79:85" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.95.e.1" text="NSAIDs" type="Drug_Class"><Normalization><mmtx cui="C0003211" phraseText="NSAIDs" preferredWord="Anti-Inflammatory Agents, Non-Steroidal" semType="phsu"/><RxNorm RxCui="889"/></Normalization></entity><entity charOffset="43:56|64:73" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.95.e.2" text="bleeding risk increased" type="Specific_Interaction"/><drugInteraction id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.95.ddi.1"><interaction trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.95.e.2"><relations><relation type="hasObject"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.95.e.0"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.95.e.1"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.95.e.1" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.95.e.0" trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.95.e.2" type="Specific_Interaction"/></sentence><sentence biomedicalEntities="3" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.96" lineNumber="111" text="Coadministration of the platelet aggregation inhibitor clopidogrel and XARELTO resulted in an increase in bleeding time for some subjects [see Clinical Pharmacology (12.3)]." type="regular"><entity charOffset="24:54" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.96.e.0" text="platelet aggregation inhibitor" type="Drug_Class"><Normalization><mmtx cui="C0032177" phraseText="Coadministration of the platelet aggregation inhibitor clopidogrel" preferredWord="Platelet Aggregation Inhibitors" semType="phsu"/><mmtx cui="C3536888" phraseText="Coadministration of the platelet aggregation inhibitor clopidogrel" preferredWord="Platelet Aggregation Inhibitor [EPC]" semType="phsu"/><RxNorm RxCui="42402"/></Normalization></entity><entity charOffset="55:66" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.96.e.1" text="clopidogrel" type="Drug"><Normalization><mmtx cui="C0070166" phraseText="Coadministration of the platelet aggregation inhibitor clopidogrel" preferredWord="clopidogrel" semType="phsu, orch"/><mmtx cui="C0070166" phraseText="Coadministration of the platelet aggregation inhibitor clopidogrel" preferredWord="clopidogrel" semType="phsu, orch"/><RxNorm RxCui="236991"/></Normalization></entity><entity charOffset="71:78" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.96.e.3" text="XARELTO" type="Drug"><Normalization><mmtx cui="C3159309" phraseText="XARELTO" preferredWord="Xarelto" semType="phsu, orch"/><RxNorm RxCui="1114199"/></Normalization></entity><entity charOffset="94:119" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.96.e.4" text="increase in bleeding time" type="Specific_Interaction"/><entity charOffset="124:137" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.96.e.6" text="some subjects" type="SPAN"/><drugClassMembership drug="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.96.e.1" drugClass="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.96.e.0"/><drugInteraction id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.96.ddi.1"><interaction trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.96.e.4"><relations><relation type="hasObject"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.96.e.3"/></relation><relation type="hasEvidence"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.96.e.6"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.96.e.1"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.96.e.1" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.96.e.3" evidence="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.96.e.6" trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.96.e.4" type="Specific_Interaction"/></sentence><sentence biomedicalEntities="2" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.97" lineNumber="113" text="Avoid concurrent use of XARELTO with other anticoagulants due to increased bleeding risk unless benefit outweighs risk. " type="regular"><entity charOffset="24:31" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.97.e.0" text="XARELTO" type="Drug"><Normalization><mmtx cui="C3159309" phraseText="concurrent use of XARELTO" preferredWord="Xarelto" semType="phsu, orch"/><RxNorm RxCui="1114199"/></Normalization></entity><entity charOffset="37:57" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.97.e.1" text="other anticoagulants" type="Drug_Class"><Normalization><mmtx cui="C0003280" phraseText="with other anticoagulants" preferredWord="Anticoagulants" semType="phsu"/><RxNorm RxCui="1429329"/></Normalization></entity><entity charOffset="65:88" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.97.e.2" text="increased bleeding risk" type="Specific_Interaction"/><drugInteraction id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.97.ddi.1"><interaction trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.97.e.2"><relations><relation type="hasPrecipitant"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.97.e.1"/></relation><relation type="hasObject"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.97.e.0"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.97.e.0" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.97.e.1" trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.97.e.2" type="Specific_Interaction"/></sentence><sentence biomedicalEntities="3" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.98" lineNumber="113" text="Promptly evaluate any signs or symptoms of blood loss if patients are treated concomitantly with aspirin, other platelet aggregation inhibitors, or NSAIDs [see Warnings and Precautions (5.2)]." type="irregular"><entity charOffset="97:104" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.98.e.0" text="aspirin" type="Drug"><Normalization><mmtx cui="C0004057" phraseText="concomitantly with aspirin," preferredWord="Aspirin" semType="phsu, orch"/><RxNorm RxCui="1191"/></Normalization></entity><entity charOffset="106:143" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.98.e.1" text="other platelet aggregation inhibitors" type="Drug_Class"><Normalization><mmtx cui="C0032177" phraseText="other platelet aggregation inhibitors," preferredWord="Platelet Aggregation Inhibitors" semType="phsu"/><RxNorm RxCui="1429329"/></Normalization></entity><entity charOffset="148:154" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.98.e.2" text="NSAIDs" type="Drug_Class"><Normalization><mmtx cui="C0003211" phraseText="NSAIDs" preferredWord="Anti-Inflammatory Agents, Non-Steroidal" semType="phsu"/><RxNorm RxCui="889"/></Normalization></entity><entity charOffset="22:53" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.98.e.3" text="signs or symptoms of blood loss" type="Caution_Interaction"><Normalization><mmtx cui="C1457887" phraseText="symptoms of blood loss" preferredWord="Symptoms" semType="sosy"/><mmtx cui="C1457887" phraseText="symptoms of blood loss" preferredWord="Symptoms" semType="sosy"/></Normalization></entity><drugInteraction id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.98.ddi.1"><interaction trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.98.e.3"><relations><relation type="hasPrecipitant"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.98.e.2"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.98.e.0"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.98.e.1"/></relation><relation type="hasObject"><ellipsisSentence id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.97" text="Avoid concurrent use of XARELTO with other anticoagulants due to increased bleeding risk unless benefit outweighs risk. "><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.97.e.0"/></ellipsisSentence></relation></relations></interaction></drugInteraction><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.98.e.0" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.98.e.2"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.98.e.1" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.98.e.2"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.98.e.0" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.98.e.1"/><pair ddi="true" e1="labelDrug" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.98.e.2"/><pair ddi="true" e1="labelDrug" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.98.e.0"/><pair ddi="true" e1="labelDrug" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.98.e.1"/></sentence><sentence biomedicalEntities="11" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.100" lineNumber="117" text="Patients with renal impairment receiving full dose XARELTO in combination with drugs classified as combined P-gp and weak or moderate CYP3A4 inhibitors (e.g., amiodarone, diltiazem, verapamil, quinidine, ranolazine, dronedarone, felodipine, erythromycin, and azithromycin) may have increases in exposure compared with patients with normal renal function and no inhibitor use, since both pathways of rivaroxaban elimination are affected." type="regular"><entity charOffset="51:58" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.100.e.0" text="XARELTO" type="Drug"><Normalization><mmtx cui="C3159309" phraseText="full dose XARELTO in combination" preferredWord="Xarelto" semType="phsu, orch"/><RxNorm RxCui="1114199"/></Normalization></entity><entity charOffset="14:30" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.100.e.1" text="renal impairment" type="SPAN"><Normalization><mmtx cui="C0035078" phraseText="Patients with renal impairment" preferredWord="Kidney Failure" semType="dsyn"/><mmtx cui="C0341697" phraseText="Patients with renal impairment" preferredWord="Renal impairment" semType="dsyn"/></Normalization></entity><entity charOffset="99:151" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.100.e.2" text="combined P-gp and weak or moderate CYP3A4 inhibitors" type="Drug_Class"><Normalization><RxNorm RxCui="67034"/></Normalization></entity><entity charOffset="282:303" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.100.e.3" text="increases in exposure" type="Increase_Interaction"/><entity charOffset="159:169" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.100.e.5" text="amiodarone" type="Drug"><Normalization><mmtx cui="C0002598" phraseText="amiodarone," preferredWord="Amiodarone" semType="phsu, orch"/><RxNorm RxCui="203114"/></Normalization></entity><entity charOffset="171:180" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.100.e.6" text="diltiazem" type="Drug"><Normalization><mmtx cui="C0012373" phraseText="diltiazem," preferredWord="Diltiazem" semType="phsu, orch"/><RxNorm RxCui="203211"/></Normalization></entity><entity charOffset="182:191" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.100.e.7" text="verapamil" type="Drug"><Normalization><mmtx cui="C0042523" phraseText="verapamil," preferredWord="Verapamil" semType="phsu, orch"/><RxNorm RxCui="11170"/></Normalization></entity><entity charOffset="193:202" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.100.e.8" text="quinidine" type="Drug"><Normalization><mmtx cui="C0034414" phraseText="quinidine," preferredWord="Quinidine" semType="phsu, orch"/><RxNorm RxCui="9068"/></Normalization></entity><entity charOffset="204:214" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.100.e.9" text="ranolazine" type="Drug"><Normalization><mmtx cui="C0073633" phraseText="ranolazine," preferredWord="ranolazine" semType="phsu, orch"/><RxNorm RxCui="35829"/></Normalization></entity><entity charOffset="216:227" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.100.e.10" text="dronedarone" type="Drug"><Normalization><mmtx cui="C0766326" phraseText="dronedarone," preferredWord="dronedarone" semType="phsu, orch"/><RxNorm RxCui="233698"/></Normalization></entity><entity charOffset="229:239" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.100.e.11" text="felodipine" type="Drug"><Normalization><mmtx cui="C0015772" phraseText="felodipine," preferredWord="Felodipine" semType="phsu, orch"/><RxNorm RxCui="4316"/></Normalization></entity><entity charOffset="241:253" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.100.e.12" text="erythromycin" type="Drug"><Normalization><mmtx cui="C0014806" phraseText="erythromycin," preferredWord="Erythromycin" semType="orch, antb"/><RxNorm RxCui="4053"/></Normalization></entity><entity charOffset="259:271" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.100.e.13" text="azithromycin" type="Drug"><Normalization><mmtx cui="C0052796" phraseText="azithromycin" preferredWord="Azithromycin" semType="orch, antb"/><RxNorm RxCui="1298839"/></Normalization></entity><drugClassMembership drug="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.100.e.5" drugClass="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.100.e.2"/><drugClassMembership drug="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.100.e.6" drugClass="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.100.e.2"/><drugClassMembership drug="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.100.e.7" drugClass="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.100.e.2"/><drugClassMembership drug="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.100.e.8" drugClass="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.100.e.2"/><drugClassMembership drug="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.100.e.9" drugClass="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.100.e.2"/><drugClassMembership drug="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.100.e.10" drugClass="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.100.e.2"/><drugClassMembership drug="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.100.e.11" drugClass="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.100.e.2"/><drugClassMembership drug="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.100.e.12" drugClass="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.100.e.2"/><drugClassMembership drug="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.100.e.13" drugClass="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.100.e.2"/><drugInteraction id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.100.ddi.1"><interaction trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.100.e.3"><relations><relation type="hasContext"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.100.e.1"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.100.e.2"/></relation><relation type="hasObject"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.100.e.0"/></relation></relations></interaction></drugInteraction><pair context="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.100.e.1" ddi="true" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.100.e.0" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.100.e.2" trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.100.e.3" type="Increase_Interaction"/></sentence><sentence biomedicalEntities="2" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.101" lineNumber="119" text="XARELTO should be used in patients with CrCl 15 to 50 mL/min who are receiving concomitant combined P-gp and weak or moderate CYP3A4 inhibitors only if the potential benefit justifies the potential risk [see Clinical Pharmacology (12.3)]." type="regular"><entity charOffset="0:7" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.101.e.0" text="XARELTO" type="Drug"><Normalization><mmtx cui="C3159309" phraseText="XARELTO" preferredWord="Xarelto" semType="phsu, orch"/><RxNorm RxCui="1114199"/></Normalization></entity><entity charOffset="91:143" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.101.e.1" text="combined P-gp and weak or moderate CYP3A4 inhibitors" type="Drug_Class"><Normalization><RxNorm RxCui="67034"/></Normalization></entity><entity charOffset="40:60" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.101.e.2" text="CrCl 15 to 50 mL/min" type="SPAN"><Normalization><mmtx cui="C1846718" phraseText="with CrCl 15" preferredWord="CREATININE CLEARANCE QUANTITATIVE TRAIT LOCUS" semType="dsyn"/></Normalization></entity><entity charOffset="18:22|144:202" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.101.e.3" text="used only if the potential benefit justifies the potential risk" type="Caution_Interaction"><Normalization><mmtx cui="C1846718" phraseText="with CrCl 15" preferredWord="CREATININE CLEARANCE QUANTITATIVE TRAIT LOCUS" semType="dsyn"/><mmtx cui="C0004093" phraseText="weak" preferredWord="Asthenia" semType="sosy"/></Normalization></entity><drugInteraction id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.101.ddi.1"><interaction trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.101.e.3"><relations><relation type="hasPrecipitant"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.101.e.1"/></relation><relation type="hasContext"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.101.e.2"/></relation><relation type="hasObject"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.101.e.0"/></relation></relations></interaction></drugInteraction><pair context="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.101.e.2" ddi="true" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.101.e.0" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.101.e.1" trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.101.e.3" type="Caution_Interaction"/></sentence><sentence biomedicalEntities="1" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.102" lineNumber="120" text="Concomitant use of other drugs affecting hemostasis increases the risk of bleeding. " type="irregular"><entity charOffset="19:51" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.102.e.0" text="other drugs affecting hemostasis" type="Drug_Class"><Normalization><mmtx cui="C0013227" phraseText="Concomitant use of other drugs" preferredWord="Pharmaceutical Preparations" semType="phsu"/><RxNorm RxCui="1429329"/></Normalization></entity><entity charOffset="52:82" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.102.e.1" text="increases the risk of bleeding" type="Specific_Interaction"/><drugInteraction id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.102.ddi.1"><interaction trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.102.e.1"><relations><relation type="hasPrecipitant"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.102.e.0"/></relation><relation type="hasObject"><ellipsisSentence id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.101" text="XARELTO should be used in patients with CrCl 15 to 50 mL/min who are receiving concomitant combined P-gp and weak or moderate CYP3A4 inhibitors only if the potential benefit justifies the potential risk [see Clinical Pharmacology (12.3)]."><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.101.e.0"/></ellipsisSentence></relation></relations></interaction></drugInteraction><pair ddi="true" e1="labelDrug" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.102.e.0"/></sentence><sentence id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.103" text="These include aspirin, P2Y12 platelet inhibitors, other antithrombotic agents, fibrinolytic therapy, and non-steroidal anti-inflammatory drugs (NSAIDs) [see Drug Interactions (7.3)]." type="negative"><entity charOffset="14:21" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.103.e.0" text="aspirin" type="Biomedical_Entity"><Normalization><mmtx cui="C0004057" phraseText="aspirin," preferredWord="Aspirin" semType="phsu, orch"/><RxNorm RxCui="1191"/></Normalization></entity><entity charOffset="105:142" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.103.e.1" text="non-steroidal anti-inflammatory drugs" type="Biomedical_Entity"><Normalization><mmtx cui="C3536840" phraseText="non-steroidal anti-inflammatory drugs (NSAIDs)" preferredWord="Nonsteroidal Anti-inflammatory Drug [EPC]" semType="phsu"/><RxNorm RxCui="1005832"/></Normalization></entity><entity charOffset="56:77" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.103.e.2" text="antithrombotic agents" type="Biomedical_Entity"><Normalization><mmtx cui="C1704311" phraseText="other antithrombotic agents," preferredWord="Antithrombotic Agents" semType="phsu"/><RxNorm RxCui="657941"/></Normalization></entity><entity charOffset="23:48" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.103.e.3" text="p2y12 platelet inhibitors" type="Biomedical_Entity"><Normalization><mmtx cui="C2962754" phraseText="P2Y12 platelet inhibitors," preferredWord="P2Y12 Platelet Inhibitor [EPC]" semType="phsu"/><RxNorm RxCui="1027718"/></Normalization></entity><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.103.e.0" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.103.e.1"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.103.e.0" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.103.e.2"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.103.e.0" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.103.e.3"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.103.e.2" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.103.e.1"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.103.e.3" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.103.e.1"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.103.e.3" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.103.e.2"/></sentence><sentence biomedicalEntities="4" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.104" lineNumber="122" text="Concomitant use of drugs that are combined P-gp and CYP3A4 inhibitors (e.g., ketoconazole and ritonavir) increases rivaroxaban exposure and may increase bleeding risk [see Drug Interactions (7.1)]." type="regular"><entity charOffset="34:69" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.104.e.0" text="combined P-gp and CYP3A4 inhibitors" type="Drug_Class"><Normalization><RxNorm RxCui="67034"/></Normalization></entity><entity charOffset="77:89" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.104.e.1" text="ketoconazole" type="Drug"><Normalization><mmtx cui="C0022625" phraseText="ketoconazole" preferredWord="Ketoconazole" semType="phsu, orch"/><RxNorm RxCui="6135"/></Normalization></entity><entity charOffset="94:103" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.104.e.2" text="ritonavir" type="Drug"><Normalization><mmtx cui="C0292818" phraseText="ritonavir" preferredWord="Ritonavir" semType="phsu, orch"/><RxNorm RxCui="85762"/></Normalization></entity><entity charOffset="115:126" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.104.e.3" text="rivaroxaban" type="Drug"><Normalization><mmtx cui="C1739768" phraseText="rivaroxaban exposure" preferredWord="rivaroxaban" semType="phsu, orch"/><RxNorm RxCui="1114195"/></Normalization></entity><entity charOffset="105:114|127:135" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.104.e.4" text="increases exposure" type="Increase_Interaction"/><entity charOffset="144:166" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.104.e.6" text="increase bleeding risk" type="Specific_Interaction"/><drugClassMembership drug="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.104.e.1" drugClass="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.104.e.0"/><drugClassMembership drug="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.104.e.2" drugClass="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.104.e.0"/><drugInteraction id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.104.ddi.1"><interaction trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.104.e.4"><relations><relation type="hasPrecipitant"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.104.e.0"/></relation><relation type="hasObject"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.104.e.3"/></relation></relations></interaction></drugInteraction><drugInteraction id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.104.ddi.2"><interaction trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.104.e.6"><relations><relation type="hasObject"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.104.e.3"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.104.e.0"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.104.e.0" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.104.e.3" trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.104.e.4" type="Increase_Interaction"/><pair ddi="true" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.104.e.0" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.104.e.3" trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.104.e.6" type="Specific_Interaction"/></sentence><sentence biomedicalEntities="2" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.106" lineNumber="126" text="When neuraxial anesthesia (spinal/epidural anesthesia) or spinal puncture is employed, patients treated with anticoagulant agents for prevention of thromboembolic complications are at risk of developing an epidural or spinal hematoma which can result in long-term or permanent paralysis [see Boxed Warning]." type="regular"><entity charOffset="5:25" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.106.e.0" text="neuraxial anesthesia" type="Drug_Class"><Normalization><mmtx cui="C0002932" phraseText="neuraxial anesthesia" preferredWord="Anesthetics" semType="phsu"/><RxNorm RxCui="NA"/></Normalization></entity><entity charOffset="109:129" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.106.e.1" text="anticoagulant agents" type="Drug_Class"><Normalization><mmtx cui="C0003280" phraseText="treated with anticoagulant agents" preferredWord="Anticoagulants" semType="phsu"/><RxNorm RxCui="923"/></Normalization></entity><entity charOffset="184:233" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.106.e.2" text="risk of developing an epidural or spinal hematoma" type="Specific_Interaction"/><drugInteraction id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.106.ddi.1"><interaction trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.106.e.2"><relations><relation type="hasObject"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.106.e.1"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.106.e.0"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.106.e.0" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.106.e.1" trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.106.e.2" type="Specific_Interaction"/></sentence><sentence id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.116" text="Avoid the use of XARELTO in patients with CrCl &lt;30 mL/min due to an expected increase in rivaroxaban exposure and pharmacodynamic effects in this patient population [see Use in Specific Populations (8.7)]." type="negative"><entity charOffset="89:100" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.116.e.0" text="rivaroxaban" type="Biomedical_Entity"><Normalization><mmtx cui="C1739768" phraseText="in rivaroxaban exposure" preferredWord="rivaroxaban" semType="phsu, orch"/><RxNorm RxCui="1114195"/></Normalization></entity><entity charOffset="17:24" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.116.e.1" text="xarelto" type="Biomedical_Entity"><Normalization><mmtx cui="C3159309" phraseText="the use of XARELTO" preferredWord="Xarelto" semType="phsu, orch"/><RxNorm RxCui="1114199"/></Normalization></entity><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.116.e.1" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.116.e.0"/></sentence><sentence id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.118" text="Avoid the use of XARELTO in patients with CrCl &lt;30 mL/min due to an expected increase in rivaroxaban exposure and pharmacodynamic effects in this patient population. " type="negative"><entity charOffset="89:100" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.118.e.0" text="rivaroxaban" type="Biomedical_Entity"><Normalization><mmtx cui="C1739768" phraseText="in rivaroxaban exposure" preferredWord="rivaroxaban" semType="phsu, orch"/><RxNorm RxCui="1114195"/></Normalization></entity><entity charOffset="17:24" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.118.e.1" text="xarelto" type="Biomedical_Entity"><Normalization><mmtx cui="C3159309" phraseText="the use of XARELTO" preferredWord="Xarelto" semType="phsu, orch"/><RxNorm RxCui="1114199"/></Normalization></entity><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.118.e.1" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.118.e.0"/></sentence><sentence biomedicalEntities="8" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.125" lineNumber="152" text="Avoid concomitant use of XARELTO with combined P-gp and strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, lopinavir/ritonavir, ritonavir, indinavir/ritonavir, and conivaptan) [see Drug Interactions (7.1)]." type="regular"><entity charOffset="25:32" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.125.e.0" text="XARELTO" type="Drug"><Normalization><mmtx cui="C3159309" phraseText="concomitant use of XARELTO" preferredWord="Xarelto" semType="phsu, orch"/><RxNorm RxCui="1114199"/></Normalization></entity><entity charOffset="38:80" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.125.e.1" text="combined P-gp and strong CYP3A4 inhibitors" type="Drug_Class"><Normalization><RxNorm RxCui="67034"/></Normalization></entity><entity charOffset="0:5" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.125.e.2" text="Avoid" type="Caution_Interaction"/><entity charOffset="88:100" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.125.e.4" text="ketoconazole" type="Drug"><Normalization><mmtx cui="C0022625" phraseText="ketoconazole," preferredWord="Ketoconazole" semType="phsu, orch"/><RxNorm RxCui="6135"/></Normalization></entity><entity charOffset="102:114" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.125.e.5" text="itraconazole" type="Drug"><Normalization><mmtx cui="C0064113" phraseText="itraconazole," preferredWord="Itraconazole" semType="phsu, orch"/><RxNorm RxCui="28031"/></Normalization></entity><entity charOffset="116:135" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.125.e.6" text="lopinavir/ritonavir" type="Drug"><Normalization><mmtx cui="C0939237" phraseText="lopinavir/ritonavir," preferredWord="lopinavir / Ritonavir" semType="phsu, orch"/><RxNorm RxCui="284640"/></Normalization></entity><entity charOffset="137:146" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.125.e.7" text="ritonavir" type="Drug"><Normalization><mmtx cui="C0292818" phraseText="ritonavir," preferredWord="Ritonavir" semType="phsu, orch"/><RxNorm RxCui="85762"/></Normalization></entity><entity charOffset="148:167" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.125.e.8" text="indinavir/ritonavir" type="Drug"><Normalization><mmtx cui="C1977393" phraseText="indinavir/ritonavir," preferredWord="Indinavir+Ritonavir" semType="orch, antb"/><RxNorm RxCui="85762"/></Normalization></entity><entity charOffset="173:183" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.125.e.9" text="conivaptan" type="Drug"><Normalization><mmtx cui="C0966107" phraseText="conivaptan" preferredWord="conivaptan" semType="phsu, orch"/><RxNorm RxCui="1294548"/></Normalization></entity><drugClassMembership drug="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.125.e.4" drugClass="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.125.e.1"/><drugClassMembership drug="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.125.e.5" drugClass="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.125.e.1"/><drugClassMembership drug="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.125.e.6" drugClass="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.125.e.1"/><drugClassMembership drug="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.125.e.7" drugClass="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.125.e.1"/><drugClassMembership drug="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.125.e.8" drugClass="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.125.e.1"/><drugClassMembership drug="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.125.e.9" drugClass="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.125.e.1"/><drugInteraction id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.125.ddi.1"><interaction trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.125.e.2"><relations><relation type="hasPrecipitant"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.125.e.1"/></relation><relation type="hasObject"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.125.e.0"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.125.e.0" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.125.e.1" trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.125.e.2" type="Caution_Interaction"/></sentence><sentence biomedicalEntities="6" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.126" lineNumber="154" text="Avoid concomitant use of XARELTO with drugs that are combined P-gp and strong CYP3A4 inducers (e.g., carbamazepine, phenytoin, rifampin, St. John's wort) [see Drug Interactions (7.2)]." type="regular"><entity charOffset="53:93" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.126.e.0" text="combined P-gp and strong CYP3A4 inducers" type="Drug_Class"><Normalization><RxNorm RxCui="67034"/></Normalization></entity><entity charOffset="101:114" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.126.e.1" text="carbamazepine" type="Drug"><Normalization><mmtx cui="C0006949" phraseText="carbamazepine," preferredWord="Carbamazepine" semType="phsu, orch"/><RxNorm RxCui="2002"/></Normalization></entity><entity charOffset="116:125" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.126.e.2" text="phenytoin" type="Drug"><Normalization><mmtx cui="C0031507" phraseText="phenytoin," preferredWord="Phenytoin" semType="phsu, orch"/><RxNorm RxCui="8183"/></Normalization></entity><entity charOffset="127:135" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.126.e.3" text="rifampin" type="Drug"><Normalization><mmtx cui="C0035608" phraseText="rifampin," preferredWord="Rifampin" semType="orch, antb"/><RxNorm RxCui="9384"/></Normalization></entity><entity charOffset="137:140|141:152" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.126.e.4" text="St. John's wort" type="Drug"><Normalization><mmtx cui="C0813171" phraseText="St. John's wort" preferredWord="ST. JOHN'S WORT EXTRACT" semType="phsu, orch"/><RxNorm RxCui="669620"/></Normalization></entity><entity charOffset="25:32" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.126.e.5" text="XARELTO" type="Drug"><Normalization><mmtx cui="C3159309" phraseText="concomitant use of XARELTO" preferredWord="Xarelto" semType="phsu, orch"/><RxNorm RxCui="1114199"/></Normalization></entity><entity charOffset="0:5" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.126.e.6" text="Avoid" type="Caution_Interaction"/><drugClassMembership drug="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.126.e.1" drugClass="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.126.e.0"/><drugClassMembership drug="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.126.e.2" drugClass="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.126.e.0"/><drugClassMembership drug="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.126.e.3" drugClass="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.126.e.0"/><drugClassMembership drug="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.126.e.4" drugClass="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.126.e.0"/><drugInteraction id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.126.ddi.1"><interaction trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.126.e.6"><relations><relation type="hasPrecipitant"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.126.e.0"/></relation><relation type="hasObject"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.126.e.5"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.126.e.5" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.126.e.0" trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.126.e.6" type="Caution_Interaction"/></sentence><sentence biomedicalEntities="3" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.137" lineNumber="166" text="Inhibitors and inducers of these CYP450 enzymes or transporters (e.g., P-gp) may result in changes in rivaroxaban exposure." type="irregular"><anaphoraRelation><antecedentSentence ID="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.136" Text="Rivaroxaban is a substrate of CYP3A4/5, CYP2J2, and the P-gp and ATP-binding cassette G2 (ABCG2) transporters. "/><anaphoraEntity charOffset="27:63" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.137.e.4" text="these CYP450 enzymes or transporters" type="Expression"/><antecedentEntity charOffset="30:109" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.136.e.0" text="CYP3A4/5, CYP2J2, and the P-gp and ATP-binding cassette G2 (ABCG2) transporters" type="Drug_Class"/></anaphoraRelation><entity charOffset="71:75" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.137.e.0" text="P-gp" type="Drug"><Normalization><RxNorm RxCui="71576"/></Normalization></entity><entity charOffset="102:113" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.137.e.1" text="rivaroxaban" type="Drug"><Normalization><mmtx cui="C1739768" phraseText="in rivaroxaban exposure." preferredWord="rivaroxaban" semType="phsu, orch"/><RxNorm RxCui="1114195"/></Normalization></entity><entity charOffset="91:101|114:122" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.137.e.2" text="changes in exposure" type="Specific_Interaction"/><entity charOffset="0:63" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.137.e.6" text="Inhibitors and inducers of these CYP450 enzymes or transporters" type="Drug_Class"><Normalization><RxNorm RxCui="NA"/></Normalization></entity><drugClassMembership drug="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.137.e.0" drugClass="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.137.e.6"/><drugInteraction id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.137.ddi.1"><interaction trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.137.e.2"><relations><relation type="hasObject"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.137.e.1"/></relation></relations></interaction></drugInteraction></sentence><sentence biomedicalEntities="7" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139" lineNumber="170" text="In drug interaction studies evaluating the concomitant use with drugs that are combined P-gp and CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin, erythromycin and fluconazole), increases in rivaroxaban exposure and pharmacodynamic effects (i.e., factor Xa inhibition and PT prolongation) were observed. " type="regular"><entity charOffset="79:114" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.0" text="combined P-gp and CYP3A4 inhibitors" type="Drug_Class"><Normalization><RxNorm RxCui="67034"/></Normalization></entity><entity charOffset="188:200|213:221" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.1" text="increases in exposure" type="Increase_Interaction"/><entity charOffset="201:212" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.3" text="rivaroxaban" type="Drug"><Normalization><mmtx cui="C1739768" phraseText="increases in rivaroxaban exposure" preferredWord="rivaroxaban" semType="phsu, orch"/><RxNorm RxCui="1114195"/></Normalization></entity><entity charOffset="188:200|257:277" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.4" text="increases in factor Xa inhibition" type="Specific_Interaction"/><entity charOffset="188:200|282:297" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.6" text="increases in PT prolongation" type="Specific_Interaction"/><entity charOffset="116:128" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.8" text="ketoconazole" type="Drug"><Normalization><mmtx cui="C0022625" phraseText="(ketoconazole," preferredWord="Ketoconazole" semType="phsu, orch"/><RxNorm RxCui="6135"/></Normalization></entity><entity charOffset="130:139" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.9" text="ritonavir" type="Drug"><Normalization><mmtx cui="C0292818" phraseText="ritonavir," preferredWord="Ritonavir" semType="phsu, orch"/><RxNorm RxCui="85762"/></Normalization></entity><entity charOffset="141:155" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.10" text="clarithromycin" type="Drug"><Normalization><mmtx cui="C0055856" phraseText="clarithromycin," preferredWord="Clarithromycin" semType="orch, antb"/><RxNorm RxCui="21212"/></Normalization></entity><entity charOffset="157:169" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.11" text="erythromycin" type="Drug"><Normalization><mmtx cui="C0014806" phraseText="erythromycin" preferredWord="Erythromycin" semType="orch, antb"/><RxNorm RxCui="4053"/></Normalization></entity><entity charOffset="174:185" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.16" text="fluconazole" type="Drug"><Normalization><mmtx cui="C0016277" phraseText="fluconazole" preferredWord="Fluconazole" semType="phsu, orch"/><RxNorm RxCui="4450"/></Normalization></entity><drugClassMembership drug="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.8" drugClass="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.0"/><drugClassMembership drug="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.9" drugClass="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.0"/><drugClassMembership drug="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.10" drugClass="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.0"/><drugClassMembership drug="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.11" drugClass="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.0"/><drugClassMembership drug="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.16" drugClass="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.0"/><drugInteraction id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.ddi.1"><interaction trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.1"><relations><relation type="hasPrecipitant"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.11"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.16"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.10"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.0"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.8"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.9"/></relation><relation type="hasObject"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.3"/></relation></relations></interaction></drugInteraction><drugInteraction id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.ddi.2"><interaction trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.4"><relations><relation type="hasPrecipitant"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.16"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.11"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.8"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.9"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.10"/></relation><relation type="hasObject"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.3"/></relation></relations></interaction></drugInteraction><drugInteraction id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.ddi.3"><interaction trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.6"><relations><relation type="hasPrecipitant"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.16"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.11"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.8"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.9"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.10"/></relation><relation type="hasObject"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.3"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.11" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.3" trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.1" type="Increase_Interaction"/><pair ddi="true" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.16" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.3" trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.1" type="Increase_Interaction"/><pair ddi="true" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.10" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.3" trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.1" type="Increase_Interaction"/><pair ddi="true" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.0" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.3" trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.1" type="Increase_Interaction"/><pair ddi="true" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.8" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.3" trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.1" type="Increase_Interaction"/><pair ddi="true" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.9" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.3" trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.1" type="Increase_Interaction"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.11" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.16"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.10" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.11"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.0" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.11"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.8" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.11"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.9" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.11"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.10" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.16"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.0" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.16"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.8" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.16"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.9" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.16"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.0" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.10"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.8" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.10"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.9" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.10"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.0" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.8"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.0" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.9"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.8" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.9"/><pair ddi="true" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.16" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.3" trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.4" type="Specific_Interaction"/><pair ddi="true" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.11" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.3" trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.4" type="Specific_Interaction"/><pair ddi="true" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.8" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.3" trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.4" type="Specific_Interaction"/><pair ddi="true" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.9" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.3" trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.4" type="Specific_Interaction"/><pair ddi="true" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.10" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.3" trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.4" type="Specific_Interaction"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.11" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.16"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.8" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.16"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.9" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.16"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.10" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.16"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.8" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.11"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.9" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.11"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.10" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.11"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.8" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.9"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.8" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.10"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.9" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.10"/></sentence><sentence id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.142" text="When data suggest a change in exposure is unlikely to affect bleeding risk (e.g., clarithromycin, erythromycin), no precautions are necessary during coadministration with drugs that are combined P-gp and CYP3A4 inhibitors." type="negative"><entity charOffset="98:110" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.142.e.0" text="erythromycin" type="Biomedical_Entity"><Normalization><mmtx cui="C0014806" phraseText="erythromycin" preferredWord="Erythromycin" semType="orch, antb"/><RxNorm RxCui="4053"/></Normalization></entity><entity charOffset="82:96" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.142.e.1" text="clarithromycin" type="Biomedical_Entity"><Normalization><mmtx cui="C0055856" phraseText="clarithromycin," preferredWord="Clarithromycin" semType="orch, antb"/><RxNorm RxCui="21212"/></Normalization></entity><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.142.e.1" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.142.e.0"/></sentence><sentence biomedicalEntities="2" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.143" lineNumber="174" text="Avoid concomitant administration of XARELTO with combined P-gp and strong CYP3A4 inhibitors [see Warnings and Precautions (5.6)]." type="regular"><entity charOffset="36:43" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.143.e.0" text="XARELTO" type="Drug"><Normalization><mmtx cui="C3159309" phraseText="concomitant administration of XARELTO" preferredWord="Xarelto" semType="phsu, orch"/><RxNorm RxCui="1114199"/></Normalization></entity><entity charOffset="49:91" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.143.e.1" text="combined P-gp and strong CYP3A4 inhibitors" type="Drug_Class"><Normalization><RxNorm RxCui="67034"/></Normalization></entity><entity charOffset="0:5" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.143.e.2" text="Avoid" type="Caution_Interaction"/><drugInteraction id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.143.ddi.1"><interaction trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.143.e.2"><relations><relation type="hasPrecipitant"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.143.e.1"/></relation><relation type="hasObject"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.143.e.0"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.143.e.0" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.143.e.1" trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.143.e.2" type="Caution_Interaction"/></sentence><sentence biomedicalEntities="5" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.145" lineNumber="178" text="Results from drug interaction studies and population PK analyses from clinical studies indicate coadministration of XARELTO with a combined P-gp and strong CYP3A4 inducer (e.g., rifampicin, phenytoin) decreased rivaroxaban exposure by up to 50%. " type="regular"><anaphoraRelation><anaphoraEntity charOffset="211:222" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.145.e.8" text="rivaroxaban" type="Drug"/><antecedentEntity charOffset="116-123" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.145.e.0" text="XARELTO" type="Drug"/></anaphoraRelation><entity charOffset="116:123" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.145.e.0" text="XARELTO" type="Drug"><Normalization><mmtx cui="C3159309" phraseText="coadministration of XARELTO" preferredWord="Xarelto" semType="phsu, orch"/><RxNorm RxCui="1114199"/></Normalization></entity><entity charOffset="131:170" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.145.e.1" text="combined P-gp and strong CYP3A4 inducer" type="Drug_Class"><Normalization><RxNorm RxCui="67034"/></Normalization></entity><entity charOffset="178:188" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.145.e.2" text="rifampicin" type="Drug"><Normalization><mmtx cui="C0035608" phraseText="rifampicin," preferredWord="Rifampin" semType="orch, antb"/><RxNorm RxCui="9384"/></Normalization></entity><entity charOffset="190:199" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.145.e.3" text="phenytoin" type="Drug"><Normalization><mmtx cui="C0031507" phraseText="phenytoin" preferredWord="Phenytoin" semType="phsu, orch"/><RxNorm RxCui="8183"/></Normalization></entity><entity charOffset="201:210|223:231" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.145.e.6" text="decreased exposure" type="Decrease_Interaction"/><entity charOffset="211:222" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.145.e.8" text="rivaroxaban" type="Drug"><Normalization><mmtx cui="C1739768" phraseText="decreased rivaroxaban exposure by" preferredWord="rivaroxaban" semType="phsu, orch"/><RxNorm RxCui="1114195"/></Normalization></entity><drugClassMembership drug="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.145.e.2" drugClass="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.145.e.1"/><drugClassMembership drug="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.145.e.3" drugClass="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.145.e.1"/><drugInteraction id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.145.ddi.1"><interaction trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.145.e.6"><relations><relation type="hasPrecipitant"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.145.e.1"/></relation><relation type="hasObject"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.145.e.8"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.145.e.1" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.145.e.8" trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.145.e.6" type="Decrease_Interaction"/></sentence><sentence biomedicalEntities="0" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.146" lineNumber="178" text="Similar decreases in pharmacodynamic effects were also observed. " type="irregular"><entity charOffset="8:44" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.146.e.0" text="decreases in pharmacodynamic effects" type="Decrease_Interaction"/><drugInteraction id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.146.ddi.1"><interaction trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.146.e.0"><relations><relation type="hasPrecipitant"><ellipsisSentence id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.145" text="Results from drug interaction studies and population PK analyses from clinical studies indicate coadministration of XARELTO with a combined P-gp and strong CYP3A4 inducer (e.g., rifampicin, phenytoin) decreased rivaroxaban exposure by up to 50%. "><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.145.e.1"/></ellipsisSentence></relation><relation type="hasObject"><ellipsisSentence id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.145" text="Results from drug interaction studies and population PK analyses from clinical studies indicate coadministration of XARELTO with a combined P-gp and strong CYP3A4 inducer (e.g., rifampicin, phenytoin) decreased rivaroxaban exposure by up to 50%. "><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.145.e.8"/></ellipsisSentence></relation></relations></interaction></drugInteraction></sentence><sentence biomedicalEntities="6" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.148" lineNumber="180" text="Avoid concomitant use of XARELTO with drugs that are combined P-gp and strong CYP3A4 inducers (e.g., carbamazepine, phenytoin, rifampin, St. John's wort) [see Warnings and Precautions (5.6)]." type="regular"><entity charOffset="53:93" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.148.e.0" text="combined P-gp and strong CYP3A4 inducers" type="Drug_Class"><Normalization><RxNorm RxCui="67034"/></Normalization></entity><entity charOffset="101:114" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.148.e.1" text="carbamazepine" type="Drug"><Normalization><mmtx cui="C0006949" phraseText="carbamazepine," preferredWord="Carbamazepine" semType="phsu, orch"/><RxNorm RxCui="2002"/></Normalization></entity><entity charOffset="116:125" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.148.e.2" text="phenytoin" type="Drug"><Normalization><mmtx cui="C0031507" phraseText="phenytoin," preferredWord="Phenytoin" semType="phsu, orch"/><RxNorm RxCui="8183"/></Normalization></entity><entity charOffset="127:135" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.148.e.3" text="rifampin" type="Drug"><Normalization><mmtx cui="C0035608" phraseText="rifampin," preferredWord="Rifampin" semType="orch, antb"/><RxNorm RxCui="9384"/></Normalization></entity><entity charOffset="137:140|141:152" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.148.e.4" text="St. John's wort" type="Drug"><Normalization><mmtx cui="C0813171" phraseText="St. John's wort" preferredWord="ST. JOHN'S WORT EXTRACT" semType="phsu, orch"/><RxNorm RxCui="669620"/></Normalization></entity><entity charOffset="25:32" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.148.e.5" text="XARELTO" type="Drug"><Normalization><mmtx cui="C3159309" phraseText="concomitant use of XARELTO" preferredWord="Xarelto" semType="phsu, orch"/><RxNorm RxCui="1114199"/></Normalization></entity><entity charOffset="0:5" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.148.e.10" text="Avoid" type="Caution_Interaction"/><drugClassMembership drug="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.148.e.1" drugClass="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.148.e.0"/><drugClassMembership drug="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.148.e.2" drugClass="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.148.e.0"/><drugClassMembership drug="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.148.e.3" drugClass="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.148.e.0"/><drugClassMembership drug="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.148.e.4" drugClass="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.148.e.0"/><drugInteraction id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.148.ddi.1"><interaction trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.148.e.10"><relations><relation type="hasObject"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.148.e.5"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.148.e.0"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.148.e.5" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.148.e.0" trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.148.e.10" type="Caution_Interaction"/></sentence><sentence id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.149" text="7.3 Anticoagulants and NSAIDs/Aspirin" type="negative"><entity charOffset="30:37" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.149.e.0" text="aspirin" type="Biomedical_Entity"><Normalization><mmtx cui="C0004057" phraseText="NSAIDs/Aspirin" preferredWord="Aspirin" semType="phsu, orch"/><RxNorm RxCui="1191"/></Normalization></entity><entity charOffset="23:29" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.149.e.1" text="nsaids" type="Biomedical_Entity"><Normalization><mmtx cui="C0003211" phraseText="NSAIDs/Aspirin" preferredWord="Anti-Inflammatory Agents, Non-Steroidal" semType="phsu"/><RxNorm RxCui="889"/></Normalization></entity><entity charOffset="4:18" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.149.e.2" text="anticoagulants" type="Biomedical_Entity"><Normalization><mmtx cui="C0003280" phraseText="7.3 Anticoagulants" preferredWord="Anticoagulants" semType="phsu"/><RxNorm RxCui="923"/></Normalization></entity><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.149.e.1" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.149.e.0"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.149.e.2" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.149.e.0"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.149.e.2" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.149.e.1"/></sentence><sentence biomedicalEntities="2" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.150" lineNumber="184" text="Single doses of enoxaparin and XARELTO given concomitantly resulted in an additive effect on anti-factor Xa activity. " type="regular"><entity charOffset="16:26" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.150.e.0" text="enoxaparin" type="Drug"><Normalization><mmtx cui="C0206460" phraseText="Single doses of enoxaparin" preferredWord="Enoxaparin" semType="phsu, carb"/><RxNorm RxCui="67108"/></Normalization></entity><entity charOffset="31:38" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.150.e.1" text="XARELTO" type="Drug"><Normalization><mmtx cui="C3159309" phraseText="XARELTO" preferredWord="Xarelto" semType="phsu, orch"/><RxNorm RxCui="1114199"/></Normalization></entity><entity charOffset="74:116" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.150.e.2" text="additive effect on anti-factor Xa activity" type="Specific_Interaction"/><drugInteraction id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.150.ddi.1"><interaction trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.150.e.2"><relations><relation type="hasObject"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.150.e.1"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.150.e.0"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.150.e.0" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.150.e.1" trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.150.e.2" type="Specific_Interaction"/></sentence><sentence biomedicalEntities="2" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.151" lineNumber="184" text="Single doses of warfarin and XARELTO resulted in an additive effect on factor Xa inhibition and PT. " type="regular"><entity charOffset="16:24" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.151.e.0" text="warfarin" type="Drug"><Normalization><mmtx cui="C0043031" phraseText="Single doses of warfarin" preferredWord="Warfarin" semType="phsu, orch, hops"/><RxNorm RxCui="11289"/></Normalization></entity><entity charOffset="29:36" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.151.e.1" text="XARELTO" type="Drug"><Normalization><mmtx cui="C3159309" phraseText="XARELTO" preferredWord="Xarelto" semType="phsu, orch"/><RxNorm RxCui="1114199"/></Normalization></entity><entity charOffset="52:91" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.151.e.2" text="additive effect on factor Xa inhibition" type="Specific_Interaction"/><entity charOffset="52:70|96:98" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.151.e.4" text="additive effect on PT" type="Specific_Interaction"/><drugInteraction id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.151.ddi.1"><interaction trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.151.e.2"><relations><relation type="hasObject"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.151.e.1"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.151.e.0"/></relation></relations></interaction></drugInteraction><drugInteraction id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.151.ddi.2"><interaction trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.151.e.4"><relations><relation type="hasObject"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.151.e.1"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.151.e.0"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.151.e.0" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.151.e.1" trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.151.e.2" type="Specific_Interaction"/></sentence><sentence biomedicalEntities="1" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.152" lineNumber="184" text="Concomitant aspirin use has been identified as an independent risk factor for major bleeding in efficacy trials. " type="irregular"><entity charOffset="12:19" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.152.e.0" text="aspirin" type="Drug"><Normalization><mmtx cui="C0004057" phraseText="Concomitant aspirin use" preferredWord="Aspirin" semType="phsu, orch"/><RxNorm RxCui="1191"/></Normalization></entity><entity charOffset="62:92" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.152.e.1" text="risk factor for major bleeding" type="Specific_Interaction"/><drugInteraction id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.152.ddi.1"><interaction trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.152.e.1"><relations><relation type="hasObject"><ellipsisSentence id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.151" text="Single doses of warfarin and XARELTO resulted in an additive effect on factor Xa inhibition and PT. "><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.151.e.1"/></ellipsisSentence></relation><relation type="hasPrecipitant"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.152.e.0"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="labelDrug" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.152.e.0"/></sentence><sentence biomedicalEntities="2" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.153" lineNumber="184" text="NSAIDs are known to increase bleeding, and bleeding risk may be increased when NSAIDs are used concomitantly with XARELTO. " type="regular"><entity charOffset="79:85" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.153.e.0" text="NSAIDs" type="Drug_Class"><Normalization><mmtx cui="C0003211" phraseText="NSAIDs" preferredWord="Anti-Inflammatory Agents, Non-Steroidal" semType="phsu"/><RxNorm RxCui="889"/></Normalization></entity><entity charOffset="114:121" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.153.e.1" text="XARELTO" type="Drug"><Normalization><mmtx cui="C3159309" phraseText="concomitantly with XARELTO." preferredWord="Xarelto" semType="phsu, orch"/><RxNorm RxCui="1114199"/></Normalization></entity><entity charOffset="43:56|64:73" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.153.e.2" text="bleeding risk increased" type="Specific_Interaction"/><drugInteraction id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.153.ddi.1"><interaction trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.153.e.2"><relations><relation type="hasPrecipitant"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.153.e.0"/></relation><relation type="hasObject"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.153.e.1"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.153.e.0" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.153.e.1" trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.153.e.2" type="Specific_Interaction"/></sentence><sentence biomedicalEntities="3" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.154" lineNumber="184" text="Coadministration of the platelet aggregation inhibitor clopidogrel and XARELTO resulted in an increase in bleeding time for some subjects [see Clinical Pharmacology (12.3)]." type="regular"><entity charOffset="24:54" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.154.e.0" text="platelet aggregation inhibitor" type="Drug_Class"><Normalization><mmtx cui="C0032177" phraseText="Coadministration of the platelet aggregation inhibitor clopidogrel" preferredWord="Platelet Aggregation Inhibitors" semType="phsu"/><mmtx cui="C3536888" phraseText="Coadministration of the platelet aggregation inhibitor clopidogrel" preferredWord="Platelet Aggregation Inhibitor [EPC]" semType="phsu"/><RxNorm RxCui="42402"/></Normalization></entity><entity charOffset="55:66" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.154.e.1" text="clopidogrel" type="Drug"><Normalization><mmtx cui="C0070166" phraseText="Coadministration of the platelet aggregation inhibitor clopidogrel" preferredWord="clopidogrel" semType="phsu, orch"/><mmtx cui="C0070166" phraseText="Coadministration of the platelet aggregation inhibitor clopidogrel" preferredWord="clopidogrel" semType="phsu, orch"/><RxNorm RxCui="236991"/></Normalization></entity><entity charOffset="71:78" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.154.e.3" text="XARELTO" type="Drug"><Normalization><mmtx cui="C3159309" phraseText="XARELTO" preferredWord="Xarelto" semType="phsu, orch"/><RxNorm RxCui="1114199"/></Normalization></entity><entity charOffset="94:119" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.154.e.4" text="increase in bleeding time" type="Specific_Interaction"/><entity charOffset="124:137" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.154.e.6" text="some subjects" type="SPAN"/><drugClassMembership drug="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.154.e.1" drugClass="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.154.e.0"/><drugInteraction id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.154.ddi.1"><interaction trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.154.e.4"><relations><relation type="hasObject"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.154.e.3"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.154.e.1"/></relation><relation type="hasEvidence"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.154.e.6"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.154.e.1" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.154.e.3" evidence="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.154.e.6" trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.154.e.4" type="Specific_Interaction"/></sentence><sentence biomedicalEntities="2" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.155" lineNumber="186" text="Avoid concurrent use of XARELTO with other anticoagulants due to increased bleeding risk unless benefit outweighs risk. " type="regular"><entity charOffset="24:31" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.155.e.0" text="XARELTO" type="Drug"><Normalization><mmtx cui="C3159309" phraseText="concurrent use of XARELTO" preferredWord="Xarelto" semType="phsu, orch"/><RxNorm RxCui="1114199"/></Normalization></entity><entity charOffset="43:57" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.155.e.1" text="anticoagulants" type="Drug_Class"><Normalization><mmtx cui="C0003280" phraseText="with other anticoagulants" preferredWord="Anticoagulants" semType="phsu"/><RxNorm RxCui="923"/></Normalization></entity><entity charOffset="65:88" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.155.e.2" text="increased bleeding risk" type="Specific_Interaction"/><drugInteraction id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.155.ddi.1"><interaction trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.155.e.2"><relations><relation type="hasPrecipitant"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.155.e.1"/></relation><relation type="hasObject"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.155.e.0"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.155.e.0" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.155.e.1" trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.155.e.2" type="Specific_Interaction"/></sentence><sentence biomedicalEntities="3" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.156" lineNumber="186" text="Promptly evaluate any signs or symptoms of blood loss if patients are treated concomitantly with aspirin, other platelet aggregation inhibitors, or NSAIDs [see Warnings and Precautions (5.2)]." type="irregular"><entity charOffset="22:53" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.156.e.0" text="signs or symptoms of blood loss" type="Caution_Interaction"><Normalization><mmtx cui="C1457887" phraseText="symptoms of blood loss" preferredWord="Symptoms" semType="sosy"/><mmtx cui="C1457887" phraseText="symptoms of blood loss" preferredWord="Symptoms" semType="sosy"/></Normalization></entity><entity charOffset="97:104" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.156.e.2" text="aspirin" type="Drug"><Normalization><mmtx cui="C0004057" phraseText="concomitantly with aspirin," preferredWord="Aspirin" semType="phsu, orch"/><RxNorm RxCui="1191"/></Normalization></entity><entity charOffset="112:143" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.156.e.3" text="platelet aggregation inhibitors" type="Drug_Class"><Normalization><mmtx cui="C0032177" phraseText="other platelet aggregation inhibitors," preferredWord="Platelet Aggregation Inhibitors" semType="phsu"/><RxNorm RxCui="42402"/></Normalization></entity><entity charOffset="148:154" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.156.e.4" text="NSAIDs" type="Drug_Class"><Normalization><mmtx cui="C0003211" phraseText="NSAIDs" preferredWord="Anti-Inflammatory Agents, Non-Steroidal" semType="phsu"/><RxNorm RxCui="889"/></Normalization></entity><drugInteraction id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.156.ddi.1"><interaction trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.156.e.0"><relations><relation type="hasPrecipitant"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.156.e.4"/></relation><relation type="hasObject"><ellipsisSentence id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.155" text="Avoid concurrent use of XARELTO with other anticoagulants due to increased bleeding risk unless benefit outweighs risk. "><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.155.e.0"/></ellipsisSentence></relation><relation type="hasPrecipitant"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.156.e.2"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.156.e.3"/></relation></relations></interaction></drugInteraction><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.156.e.2" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.156.e.4"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.156.e.3" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.156.e.4"/><pair ddi="false" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.156.e.2" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.156.e.3"/><pair ddi="true" e1="labelDrug" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.156.e.4"/><pair ddi="true" e1="labelDrug" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.156.e.2"/><pair ddi="true" e1="labelDrug" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.156.e.3"/></sentence><sentence biomedicalEntities="11" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.158" lineNumber="190" text="Patients with renal impairment receiving full dose XARELTO in combination with drugs classified as combined P-gp and weak or moderate CYP3A4 inhibitors (e.g., amiodarone, diltiazem, verapamil, quinidine, ranolazine, dronedarone, felodipine, erythromycin, and azithromycin) may have increases in exposure compared with patients with normal renal function and no inhibitor use, since both pathways of rivaroxaban elimination are affected." type="regular"><entity charOffset="14:30" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.158.e.0" text="renal impairment" type="SPAN"><Normalization><mmtx cui="C0035078" phraseText="Patients with renal impairment" preferredWord="Kidney Failure" semType="dsyn"/><mmtx cui="C0341697" phraseText="Patients with renal impairment" preferredWord="Renal impairment" semType="dsyn"/></Normalization></entity><entity charOffset="51:58" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.158.e.1" text="XARELTO" type="Drug"><Normalization><mmtx cui="C3159309" phraseText="full dose XARELTO in combination" preferredWord="Xarelto" semType="phsu, orch"/><RxNorm RxCui="1114199"/></Normalization></entity><entity charOffset="99:151" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.158.e.2" text="combined P-gp and weak or moderate CYP3A4 inhibitors" type="Drug_Class"><Normalization><RxNorm RxCui="67034"/></Normalization></entity><entity charOffset="159:169" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.158.e.3" text="amiodarone" type="Drug"><Normalization><mmtx cui="C0002598" phraseText="amiodarone," preferredWord="Amiodarone" semType="phsu, orch"/><RxNorm RxCui="203114"/></Normalization></entity><entity charOffset="171:180" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.158.e.4" text="diltiazem" type="Drug"><Normalization><mmtx cui="C0012373" phraseText="diltiazem," preferredWord="Diltiazem" semType="phsu, orch"/><RxNorm RxCui="203211"/></Normalization></entity><entity charOffset="182:191" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.158.e.5" text="verapamil" type="Drug"><Normalization><mmtx cui="C0042523" phraseText="verapamil," preferredWord="Verapamil" semType="phsu, orch"/><RxNorm RxCui="11170"/></Normalization></entity><entity charOffset="193:202" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.158.e.6" text="quinidine" type="Drug"><Normalization><mmtx cui="C0034414" phraseText="quinidine," preferredWord="Quinidine" semType="phsu, orch"/><RxNorm RxCui="9068"/></Normalization></entity><entity charOffset="204:214" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.158.e.7" text="ranolazine" type="Drug"><Normalization><mmtx cui="C0073633" phraseText="ranolazine," preferredWord="ranolazine" semType="phsu, orch"/><RxNorm RxCui="35829"/></Normalization></entity><entity charOffset="216:227" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.158.e.8" text="dronedarone" type="Drug"><Normalization><mmtx cui="C0766326" phraseText="dronedarone," preferredWord="dronedarone" semType="phsu, orch"/><RxNorm RxCui="233698"/></Normalization></entity><entity charOffset="229:239" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.158.e.9" text="felodipine" type="Drug"><Normalization><mmtx cui="C0015772" phraseText="felodipine," preferredWord="Felodipine" semType="phsu, orch"/><RxNorm RxCui="4316"/></Normalization></entity><entity charOffset="241:253" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.158.e.10" text="erythromycin" type="Drug"><Normalization><mmtx cui="C0014806" phraseText="erythromycin," preferredWord="Erythromycin" semType="orch, antb"/><RxNorm RxCui="4053"/></Normalization></entity><entity charOffset="259:271" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.158.e.11" text="azithromycin" type="Drug"><Normalization><mmtx cui="C0052796" phraseText="azithromycin" preferredWord="Azithromycin" semType="orch, antb"/><RxNorm RxCui="1298839"/></Normalization></entity><entity charOffset="282:303" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.158.e.21" text="increases in exposure" type="Increase_Interaction"/><drugClassMembership drug="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.158.e.3" drugClass="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.158.e.2"/><drugClassMembership drug="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.158.e.4" drugClass="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.158.e.2"/><drugClassMembership drug="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.158.e.5" drugClass="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.158.e.2"/><drugClassMembership drug="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.158.e.6" drugClass="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.158.e.2"/><drugClassMembership drug="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.158.e.7" drugClass="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.158.e.2"/><drugClassMembership drug="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.158.e.8" drugClass="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.158.e.2"/><drugClassMembership drug="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.158.e.9" drugClass="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.158.e.2"/><drugClassMembership drug="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.158.e.10" drugClass="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.158.e.2"/><drugClassMembership drug="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.158.e.11" drugClass="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.158.e.2"/><drugInteraction id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.158.ddi.1"><interaction trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.158.e.21"><relations><relation type="hasObject"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.158.e.1"/></relation><relation type="hasContext"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.158.e.0"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.158.e.2"/></relation></relations></interaction></drugInteraction><pair context="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.158.e.0" ddi="true" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.158.e.1" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.158.e.2" trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.158.e.21" type="Increase_Interaction"/></sentence><sentence biomedicalEntities="2" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.159" lineNumber="192" text="XARELTO should be used in patients with CrCl 15 to 50 mL/min who are receiving concomitant combined P-gp and weak or moderate CYP3A4 inhibitors only if the potential benefit justifies the potential risk [see Clinical Pharmacology (12.3)]." type="regular"><entity charOffset="0:7" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.159.e.0" text="XARELTO" type="Drug"><Normalization><mmtx cui="C3159309" phraseText="XARELTO" preferredWord="Xarelto" semType="phsu, orch"/><RxNorm RxCui="1114199"/></Normalization></entity><entity charOffset="40:60" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.159.e.1" text="CrCl 15 to 50 mL/min" type="SPAN"><Normalization><mmtx cui="C1846718" phraseText="with CrCl 15" preferredWord="CREATININE CLEARANCE QUANTITATIVE TRAIT LOCUS" semType="dsyn"/></Normalization></entity><entity charOffset="91:143" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.159.e.2" text="combined P-gp and weak or moderate CYP3A4 inhibitors" type="Drug_Class"><Normalization><RxNorm RxCui="67034"/></Normalization></entity><entity charOffset="18:22|144:202" id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.159.e.3" text="used only if the potential benefit justifies the potential risk" type="Caution_Interaction"><Normalization><mmtx cui="C1846718" phraseText="with CrCl 15" preferredWord="CREATININE CLEARANCE QUANTITATIVE TRAIT LOCUS" semType="dsyn"/><mmtx cui="C0004093" phraseText="weak" preferredWord="Asthenia" semType="sosy"/></Normalization></entity><drugInteraction id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.159.ddi.1"><interaction trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.159.e.3"><relations><relation type="hasObject"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.159.e.0"/></relation><relation type="hasContext"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.159.e.1"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.159.e.2"/></relation></relations></interaction></drugInteraction><pair context="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.159.e.1" ddi="true" e1="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.159.e.0" e2="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.159.e.2" trigger="Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.159.e.3" type="Caution_Interaction"/></sentence><positiveExamples number="61"/><negativeExamples number="204"/></document>